The preparation of isotopically labelled organic nitrogenous compounds by Robson, John
University of Wollongong 
Research Online 
University of Wollongong Thesis Collection 
1954-2016 University of Wollongong Thesis Collections 
1972 
The preparation of isotopically labelled organic nitrogenous compounds 
John Robson 
Wollongong University College 
Follow this and additional works at: https://ro.uow.edu.au/theses 
University of Wollongong 
Copyright Warning 
You may print or download ONE copy of this document for the purpose of your own research or study. The University 
does not authorise you to copy, communicate or otherwise make available electronically to any other person any 
copyright material contained on this site. 
You are reminded of the following: This work is copyright. Apart from any use permitted under the Copyright Act 
1968, no part of this work may be reproduced by any process, nor may any other exclusive right be exercised, 
without the permission of the author. Copyright owners are entitled to take legal action against persons who infringe 
their copyright. A reproduction of material that is protected by copyright may be a copyright infringement. A court 
may impose penalties and award damages in relation to offences and infringements relating to copyright material. 
Higher penalties may apply, and higher damages may be awarded, for offences and infringements involving the 
conversion of material into digital or electronic form. 
Unless otherwise indicated, the views expressed in this thesis are those of the author and do not necessarily 
represent the views of the University of Wollongong. 
Recommended Citation 
Robson, John, The preparation of isotopically labelled organic nitrogenous compounds, Master of Science 
thesis, Department of Chemistry, University of Wollongong, 1972. https://ro.uow.edu.au/theses/2636 
Research Online is the open access institutional repository for the University of Wollongong. For further information 
contact the UOW Library: research-pubs@uow.edu.au 

THE PREPARATION OF ISOTOPICALLY LABELLED ORGANIC 
NITROGENOUS COMPOUNDS 
A THESIS 
submitted in fulfilment of the requirements for the degree of 
MASTER OF SCIENCE 
of The University of New South Wales 
by 
JOHN ROBSON 
BESEE^t:'— 
UNIVERSITY 
WOLLONGONG . 
UBRARY ' Wollongong University College 
The University of New South 
Wales 
December 1972 
€oSc>éS 
(iii) 
SUMMARY 
In order to develop new compounds for the rapid and effective 
diagnosis of melanoma in vivo, a number of radioisotopically labelled 
quinoline derivatives were prepared and tested in experimental animals. 
131 
Because of the intrinsic necessity to introduce I into the molecule 
at the latest possible state of the synthesis, the labelled compounds 
were prepared mainly through the Sandmeyer reaction. 
During the course of this work twenty new quinoline derivatives 
and two new acrylate intermediates were synthesised. In addition 
three monoiodoquinolines and two 4-amino-X-iodoquinolines labelled with 
131 
I together with five tritioquinolines were prepared for the first 
time. The yields of several of the reported preparative procedures 
were also greatly improved. 
The structural factors influencing the uptake of the labelled 
quinoline derivatives by melanomas and other pigmented tissues were 
elucidated from the distribution of the radioactive label in the 
various tissues of the experimental animals. In this way, it was 
established that : 
(i) Monoiodoquinolines had no selective affinity for pigmented 
tissue 
(ii) 4-Aminoquinoline had no selective affinity for pigmented 
tissue 
(iii) 4-Amino-X-iodoquinoline derivatives had a highly selective 
affinity for pigmented tissue 
(iv) In respect of the affinity for pigmented tissue 6-iodo-4-
aminoquincline and 7-iodo-4-aminoquinoline were equivalent 
(v) About eight times as much radioactivity from 4-amino-6-iodo-
quinoline and 4-amino-7-iodoquinoline concentrated in 
melanomas by parenteral administration than if given orally 
(vi) By contrast; higher concentrations of labelled 4-(3-dimethyl-
aminopropylamino)-7-iodoquinoline were found in melanomas 
when given orally than by intraperitoneal injection. 
123 
The possible use of I as an alternative in melanoma diagnosis 
is discussed. 
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INTRODUCTION 
MELANOMA AND ITS DETECTION 
In tropical and subtropical climates where the population is 
exposed to high intensity solar radiation for much of the year the 
incidence of skin cancer in fair skinned people of white races is 
considerably higher than in the more temperate regions of the Earth. ^ 
A causal relationship has been established between the degree of ultra 
violet irradiation of the skin and the incidence of melanoma, a tumour 
of the melanocytes, i.e. of the cells in which pigment is produced in 
2 the body. Although this is a comparatively rare condition in non 
white races (even in albinos) there has been a progressive increase 
2 
throughout the world in the mortality attributed to this cause. In 
Australia, where there are long hours of strong sunlight and a 
predominantly white population of Anglo-Saxon origin, the death rate 
from melanoma is the highest in the world and it has been observed to 2 
increase with proximity to the Equator. Where a substantial 
proportion of the population is employed in outdoor activities, such 
as in the pastoral industries in Queensland, the death rate is 
particularly high but the mortality does not reflect the exceptionally 
2 
high incidence of the tumour or of skin cancer in general in this 
State. ̂  Because there is a great public awareness of the danger of 
malignant skin conditions patients usually seek prompt medical attention 
so that melanoma can be diagnosed and treated at an early stage when 
cures can be readily effected. 
It is comparatively easy to diagnose melanoma as it is readily 
accessible in the skin. However incisional biopsy of skin lesions 
is rigorously avoided since the surgical procedure might result in 
3 
the dissemination of malignant cells throughout the body. Once 
metastatic melanoma occurs deep within the body and the lesions cannot 
be detected by radiography or palpation, it is desirable to define the 
extent and the spread of the disease without surgical exploration. 
One such method for the detection and location of malignant lesions 
relies on the binding of a compound labelled with a radioactive nuclide 
to the malignant cells or to a component thereof. If sufficient of 
the labelled compound is concentrated in the melanoma to differentiate 
it from the surrounding tissue, and provided the decay of the radio-
active nuclide is accompanied by the emission of gamma radiation, then 
the tumour can be detected from outside the body. 
Since the success and limitations of this technique to detect 
internal tumours depend on the measurement of the distribution of 
radioactivity within the body it is fortunate that considerable 
technical advances have been made within recent years in the develop-
ment of equipment for this purpose. A number of instruments are 
available commercially, among them the gamma camera which can provide 
an oscilloscope display of the distribution of radioactivity detected 
by a large area scintillation crystal and data can be recorded for 
subsequent computer analysis to assist evaluation of the visual display. 
The quality of the display and therefore the reliability of the 
diagnosis depends on sufficient radiation reaching the scintillation 
crystal for recognition of the difference between a lesion and the 
background radiation from the surrounding tissue. If a tumour is 
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FIG.l. BIOSYNTHESIS OF M E L A N I N A N D E P I N E P H R I N E . 
small or does not concentrate the radioactive compound well enough 
then it can be overlooked. This is less likely to occur when a 
rectilinear scanner is used since this instrument is more suitable 
than the gamma camera for the measurement of low levels of radio-
4 
activity. In this case the intensity of radiation detected by a 
scintillation counter is recorded either in analogue form on chart 
or photographically as a series of profiles across the body at small 
incremental distances. In addition to these relatively sophisticated 
instruments useful information can be obtained by a simple counting 
procedure over areas of the body with a gamma scintillation counter. 
This method has some advantages since counting in a small area can be 
carried out over a long enough time period to obtain statistically 
significant results. The areas of the body to be measured in this 
way can be selected on the basis of their known propensity to be 
sites of metastases. 
Melanin Precursors 
Initially the use of a precursor of melanin labelled with a 
radioactive nuclide had been proposed since biosynthesis to melanin 
in the body (Fig.l^) accompanied by its concentration in pigmented 
tissue would enable detection of melanomas with the help of the 
14 6 equipment described above. However with C labelled tyrosine (1) 
3 14 
and either H or C labelled dopa (dl-3,4-dihydroxyphenylalanine) 
the radioactivity was incorporated not only into pigmented 
tissue but also into the adrenals. Although these compounds were 
known to be also precursors of epinephrine (3) which is found in the 
adrenals it had been hoped that the distribution of the labelled 
compounds between the two biosynthetic routes would be in favour of 
the production of radioactive melanin. In fact the experiments 
showed that almost equal amounts of radioactivity were concentrated 
in both melanoma and adrenals and higher concentrations were found 
only in rapidly growing, deeply pigmented tumours. 
3 14 
Despite the difficulty of detecting concentrations of H or G 
in melanomas from outside the body (since they emit only soft beta 
radiation) the absorption of this soft beta radiation within a very 
small depth of tissue enables these nuclides to destroy the cells 
in which the labelled compounds are concentrated. Tritium labelled 
compounds are particularly suitable for this purpose as the radiation 14 
damage is limited to the immediately surrounding tissue whereas C 
labelled compounds can incorporate, by some unforseen reaction, into 
other tissues and damage healthy tissue. This hazard is considerably 
less with tritium labelled compounds because this nuclide is excreted 
relatively rapidly from the body and therefore would be less likely to 
excessively irradiate other tissues. Unfortunately much of the 
tritium in labelled dopa proved to be labile. Any possible use of 
this compound to attack melanoma was abandoned as it was thought that 
insufficient radioactivity would be concentrated in the tumour to bring 
about therapy.^ Furthermore it was estimated that the quantity of 
H labelled compound for radiotherapy would result in the excessive 
irradiation of some organs e.g. the gut. 
Two attempts have been made to prepare melanin precursors 
labelled with a nuclide emitting gamma radiation for use in the 
detection of melanoma. By taking advantage of the ability of dopa 
51 to form chelates with metal ions, its Cr chromium chelate was tested 
8 51 in tumour bearing mice. Although the distribution of Cr differed 
14 
from that of C labelled dopa the highest concentrations were found 
in the adrenals and in the melanoma. A major drawback with this 
material is the emission of gamma radiation from only 87o of the 51 
disintegrations of Cr. Consequently a greater quantity of this 
nuclide is required to enable detection to be made from outside the 
body. The absence of further reports in the literature suggests 
that the unfavourable nuclear properties of ^^Cr have led to the 
discontinued use of this chelate. 
To overcome the problem of labelled melanin precursors giving 
rise to both melanin and epinephrine, compounds closer to the final 9 stage of melanogenesis were tested in animals. One such compound, 
131 the gamma emitting 5,6-dihydroxy-7-iodoindole- I, proved to be 
too unstable in air to permit testing. While 5,6-diacetoxy-7-
131 
iodoindole- I was sufficiently stable, it displayed no selective 
concentration in pigmented tissue. It was thought that this result 
might be due to the introduction of the iodo group and consequent 
impairment of the subsequent biological transformation of this melanin 
precursor. When a similar lack of specificity was found for 5,6-
diacetoxyindole-2-^^C, the failure of the labelled compound to 
concentrate in pigmented tissue could not be attributed to the 
presence of an iodo group. Attempts to introduce radioactivity 
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FIG.2. QUINOLINE AND THE DERIVATIVES CONCENTRATED IN 
PIGMENTED TISSUE, 
into melanotic tissue by means of labelled melanin precursors have 
been discontinued since some derivatives of quinoline (4, Fig.2.) 
not known as precursors were found to concentrate in melanin 
containing tissue by a mechanism as yet unexplained. 
Quinoline Derivatives 
(a) In Diagnosis 
The search for a melanoma selective radioactive compound led to 
the antimalarial drug, 4-(4-diethylamino-l-methylbutylamino)-7-
chloroquinoline (5) known as chloroquine.^^ The affinity of this 
compound for melanin was first recognised by its deposition in the 
pigmented tissues of the eye to such an extent that prolonged 
administration of this drug has been known to result in retinopathy^^ 
i.e. pathological changes in the retina with impairment of vision. 
Concentration of chloroquine by the pigmented eye tissues is 
remarkably specific and it has been shown to accumulate in the foetal 
12 eye in animals. Incorporation into eye tissues occurs rapidly, 
within 48 hours of administration, with preferential storage in the 
13 
iris and the choroid. Once taken up by these tissues chloroquine 
is released only over a long period. 
Although chloroquine shows a number of useful pharmacological 
properties e.g. as an anti-inflammatory agent in the treatment of 
rheumatoid arthritis its antimalarial activity is superior to all 
other compounds tested in the antimalaria programme conducted by the 14 
U.S. Office of Scientific Research and Development from 1941 to 1945. 
The corresponding iodo compound, 4-(4-diethylamino-l-methylbutylamino)-
7-iodoquinoline (6), named iodoquine and 4-(3-dimethyla^linopropyl-
amino)-7-iodoquinoline (7) which differs from iodoquine only in the 
nature of the side chain, have less antimalarial potency ^^ but, 
also bind to melanin.^^'^^ When each of the above iodo compounds 
125 131 
labelled with either I or I were tested, preferential 
concentration of the radioactivity was found in the pigmented 
tissue. Melanomas in animals ^nd melanotic tumours in humans 
were located by scanning when they could not be detected radio-
graphically or by palpation.^^'^^ In contrast radioiodine in the 
form of sodium iodide showed no preferential concentration in pigmented 
10,20 
tissue. 
On subsequent evaluation of the use of the labelled quinoline 
derivatives in the detection of melanomas within the body by means 
of the radioactivity concentrated in them, the results showed good 18 
correlation with the clinical conditions of the patients. Because 
the affinity displayed by the radioiodine labelled compounds for 
melanotic tissue depends on the intensity of pigmentation i.e. on the 
melanin concentration, results of limited value only were obtained 
from poorly pigmented tumours which did not concentrate sufficient 18 
radioactivity to permit their unambiguous detection. This situation 
occurs in the amelanotic melanomas where malignant cells have almost 
entirely lost the ability to produce melanin. Poor uptake of radio-
activity were also observed in tumours where there was extensive 
necrosis and thus contained fewer functioning cells. In addition 
it has been estimated that very small lesions (less than 0.7 cm 
diameter) could escape detection on account of the very small amount 
21 of radioactivity associated with them. 
A useful diagnostic application of the labelled quinoline 
derivatives grew out of an investigation of a case of intraocular 
19 
melanoma. In this condition there is a primary melanotic tumour 
within the eye and which is therefore not accessible for histopath-
ological examination. Although the practice is to enucleate the 
eye whenever this particular form of melanoma is believed to exist, 
this operation turns out to have been unnecessary in 197o of the 
22 
cases. A technique was evolved whereby radioiodine labelled iodo-
quine or 4-(3-dimethylaminopropylamino)-7-iodoquinoline is administered 
to patients with suspected intraocular melanoma and measurements of 
the radioactivity are made over each eye for a number of days. If 
a consistently higher value is found in the affected eye this evidence 
is accepted as confirming the diagnosis of melanoma. After examination 
of a number of cases in this way it was claimed that the diagnosis can 22 
be made with 957» confidence. This is a relatively new method for the 
diagnosis of intraocular melanoma and so far its potential has not been 
adequately assessed. 
(b) In Radiotherapy 125 131 Both the I and the I labelled quinolines have been evaluated 
131 for the diagnosis of melanomas but only I was found suitable for 
the destruction of melanotic tumours by the radioactivity concentrated 
23 
in them in the form of labelled quinoline derivatives. The properties 
of the nuclide relevant to this purpose are:-
(i), the emission of beta radiation to kill the cells to which 
the radiation penetrates and 
(ii), a half life of 8 days allowing delivery of the radiation 
dose before much of the labelled compound is released from pigmented 
tissue. A small daily excretion has been observed to occur although 
the labelled quinolines appear firmly bound to melanin. 
131 The use of I labelled compounds in therapy is often associated 
with some problems. In this case loss of the radioactive label by 
131 
metabolism or isotopic exchange can provide a source of I which 
may concentrate in the thyroid and injure this gland. In addition 
the labelled quinoline derivatives would be concentrated to some 
extent in normal pigmented tissues as well as in melanomas. The 
limitations of this treatment therefore depend on the extent to 
which the functions of specialised tissues adjacent to pigmented 131 tissue are damaged by the radiation from the I taken up by the 
131 pigmented tissue e.g.damage to the retina from I in pigmented eye tissue 
131 
To assess the potential of I labelled iodoquine and analogous 
compounds in the treatment of melanoma, therapeutic doses of 50 mCi 
or more of 4-(3-dimethylaminopropylamino)-7-iodoquinoline were 23 
administered to dogs suffering from melanoma. It had been estimated 
that sufficient radioactivity would be concentrated in the tumour to 
destroy the malignant tissue. Although two dogs died before any effect 
of radiation on the tumour could be seen, the remaining dog survived 
to the end of the experimental period and on examination of this 
animal encouraging results were obtained. The metastatic lesions 
had completely regressed and, significantly, radiation damage of the 
eyes was absent not only in these dogs but also in a control group 
of non tumour bearing dogs which had received similar quantities of 
the radioactive compound. Histopathological examination of the eyes 
up to 8 months after the treatment revealed no evidence of damage or 
abnormality. 
(c) Structure-Activity Relationships 
No mechanism has yet been established to explain the affinity of 
the 4-aminoquinoline derivatives for melanotic tissue but attempts 
have been reported in the literature to relate affinity to the 
position and nature of some substituent groups. The significance of 
the position of the iodo group in the 4-aminoquinoline derivatives 
to the preferential uptake by pigmented tissue has been examined in 
animals by comparison between the radioactivity incorporated into 
pigmented tissue from radioiodine labelled 4-(3-dimethylaminopropy-
24 lamino)-6-iodoquinoline and the 7-iodo derivative. While no 
significant differences were found between the 6 and 7 substituted 
derivatives, there were inconsistencies in the uptake of the 7-iodo 
24 
derivative. The high dose rate of compound and different 
experimental conditions employed for the tests suggest that this 
conclusion should be treated with caution. 
It has also been concluded that a basic group in the 4-position 
25 
is necessary although only a limited number of groups have been 
examined. A preferential uptake was found for 7-iodoquinoline 
substituted in the 4 position with the 4-methylpentylamino group or 
the 3-dimethylaminopropoxy group but this was less than with the 
3-dimethylaminopropylamino group. In contrast, all specificity for 
pigmented tissue was lost with a hydroxy group in the 4 position. 
Other Compounds 
The binding of some phenothiazine derivatives, e.g. chlorpromazine 
(2-chloro-lO-dimethylaminopropylphenothiazine) to melanin was 
demonstrated at about the same time as the similar property of 
26 
chloroquine. However the development of a radioactive phenothiazine 
derivative for use in melanoma detection failed to eventuate due to 
difficulty in introducing a suitable radioactive nuclide. Meanwhile 
the successful application of radioiodine labelled quinoline derivatives 
for this purpose had been achieved^^ and consequently work on 
phenothiazine derivatives was discontinued. 
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FIG. 3a. PREPARATION OF 4-AMINOQUINOLINES BY CYCLODEHYDRATION 
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PREPARATION OF 4-AMINOQUINCLINE DERIVATIVES 
Methods of Synthesis 
Since both of the radioiodine compounds with which melanoma has 
been detected previously are 4-aminoquinoline derivatives, the methods 
by which 4-aminoquinoline and its derivatives can be prepared are 
important to this project. Once their exceptional antimalarial 
potency had been recognised many 4-aminoquinoline derivatives were 
tested for antimalarial activity and a consequence of this work was 
the development of a number of general methods for the preparation 
of those quinoline derivatives. The starting material common to 
many synthetic routes was the same aniline derivative as can be seen 
from the principal methods described below : 
27 
(a) Cyclodehydration of a p-Anilinoacrylamide (Fig.3a) 
p - a n i l i n o a c r y l a m i d e s (11), prepared by the reaction of an 
aniline derivative (8) with ethyl orthoformate (9) and the amide 
of an acid possessing an active methylene group (10) cyclise with 
phosphorus pentoxide to yield 4-aminoquinoline derivatives (12) with 
a substituent in the 3 position. A side chain on the 4-amino group 
is derived from the substituent on the original amide (10). When 
this reaction was carried out with 3-chloroaniline cyclisation of 
the p - 3 - c h l o r a n i l i n a c r y l a t e formed could lead to either the 5 - c h l o r o 
or the 7-chloro derivative. In fact only the 7-chloro derivative 
was found however it has not been established whether the 7 
substituted quinoline derivative is the predominant isomer formed 
N H 
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FIG.3b. PREPARATION OF 4-CHLOROQUINOLINE THROUGH THE SKRAUP REACTION. 
from other meta substituted anilines. This synthesis has the 
advantage of leading directly to a 4-aminoquinoline but requires a 
substituent to activate the methylene group in the amide (10) which 
leads to an unwanted substituent in position 3 of the quinoline. 
(b) Preparation of 4-Chloroquinoline Derivatives via the Skraup 
Reaction 
The preparative methods below do not result directly in a 
4-aminoquinoline derivative but they lead to the corresponding 
4-chloroquinoline intermediate in which the chloro group can be 
replaced by the desired amino group. Quinoline derivatives (14) 
can be prepared from aniline and its derivatives (8) by the Skraup 
reaction, i.e. by reaction with glycerol (13) in sulphuric acid and 
an oxidising agent e.g. arsenic acid. The positions of substituents 
in the benzene ring of the quinoline derivative (14) are controlled 
by the substitution of the aniline derivative (8). Thus an ortho 
group and a para group lead to the 8 substituted and the 6 substituted 
28 
quinoline derivatives respectively while a mixture of the 5 and 7 
substituted quinolines is obtained from meta substituted anilines. 
The relative proportions of the isomers have been shown to depend on 29 30 
the nature of the substituent group ' e.g. meta directing groups 
give mainly 5 and some 7 substituted quinolines and the reverse 
29 
applies for ortho, para directing groups. 
Once the required quinoline derivative has been prepared it can 
•31 33 3 ̂ 
be oxidised to the N-oxide (15) ' ' ' from which a mixture of 
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FIG.3c. PREPARATION OF 4-CHLOROQUINOLINES BY THE CONRAD LIMPACH SYNTHESIS. 
the 2-chloro (17), the 3-chloro (18) and the 4-chloroquinoline 
derivative (16) is produced on treatment with a strong chlorinating 
31 32 
agent, e.g. sulphury1 chloride. ' Since separation of the 
isomers of the chloroquinoline derivatives presents problems an 
alternative route for the exclusive preparation of the 4-chloro-
quinoline derivative (16) from the N-oxide derivative (15) has been 
35 described. This approach relies on the preparation of the 4-
nitroquinoline-l-oxLde derivative (19) by selective nitration of 
o 3 6 the N-oxide (15) which takes place in the 4 position above 40 
37 but at lower temperatures also in the 5 and 8 positions; the only 
exception is the nitration of 6-nitroquinoline in the 4 position which 
38 39 
takes place at room temperature. ' In the subsequent reaction to 
obtain the 4-chloroquinoline derivative (16) treatment of the 4-nitro-
quinoline-l-oxide derivative (19) with phosphorus trichloride results 
not only in the reduction of the N-oxide function but also in the 40 displacement of the nitro group by a chloro group. 
41 42 
(c) Conrad Limpach Synthesis (Fig.3c) ' 
After condensation of an aniline derivative (8) with ethyl 
ethoxalylacetate (20) the anilinosuccinic ester (21) formed can be 
cyclised to produce the 2-carbethoxy-4-hydroxyquinoline derivative 
41 
(22). Hydrolysis of this ester to the carboxylic acid (23) followed 
by decarboxylation results in the formation of the 4-hydroxyquinoline 
derivative (24) which can be converted to the 4-chloroquinoline 
derivative (16) in the usual way. However both the 5 and 7 sub-
stituted quinoline derivatives are obtained from meta substituted 
anilines by this synthesis. 
C O O C ^ H s 
\ c O O C 2 H 5 
II 
(26) 
COOH 
(28) 
COOC,H 2^15 
(27) 
(24) (16) 
FIG.3d PREPARATION OF 4-CHLOROQUINOLINES BY THE DXETHYLETHOXYMETHYLENE 
MALONATE METHOD. 
(d) Ethoxymethy1enemaIonic Ester Method (Fig.3d) 
This synthesis has many points of similarity to the Conrad 
Limpach method described above as an aniline derivative (8) is 
condensed with diethyl ethoxymethy1enemalonate (25) and the aerylate 
formed (26) is cyclised to give the 3-carbethoxy-4-hydroxyquinoline 
43 
derivative (27). The essential difference between the methods 
stems from the fact that meta substituted anilines result in the 
almost complete formation of the 7 substituted quinoline derivative, 
instead of a mixture of the 5 and 7 substituted isomers. This feature 
is of particular value since this is the route employed in the 
preparation of the 7-halogenoquinoline derivatives which comprise a 
large proportion of the materials tested for affinity for pigmented 
tissue. The synthesis is completed by hydrolysis of the 3-carbe-
thoxy-4-hydroxyquinoline derivatives (27) to the carboxylic acid (28) 
which is decarboxylated and the resulting 4-hydroxyquinoline derivative 
(24) converted to the 4-chloroquinoline derivative (16) in the usual 
way. 
(e) Conversion of 4-Chloro to 4-Aminoquinoline Derivatives 
Derivatives of 4-chloroquinoline are known to reach with either 
41 44 45 ammonia ' ' (to produce the corresponding derivatives of 4-
aminoquinoline), or with a primary amine when a side chain is required 
42 
on the 4-amino group. The actual conditions under which the 
reaction will take place depend on the positions of the substituent 
groups in the quinoline ring and, in general, it has been found that 
milder conditions are required when they occupy positions in the 
benzene ring than if they are in the 2 or 3 positions of the hetero 
46 ring. On the other hand secondary amines are reluctant to react 
47 with 4-chloroquinoline derivatives under similar conditions. Since 
it has been established that replacement of a chloro group by an 
42 
amino group occurs in the 4 position but not in the 5, 6, 7 or 8 
46 positions then the 4,X-dihalogenoquinolines give only the 4-amino-
X-halogenoquinoline derivatives; replacement of the second halogeno 
group takes place only under severe conditions of temperature and 
45 pressure. 
Labelling with Radioiodine 
25 
In previous work, radioiodine was introduced into all the 
quinoline derivatives tested for uptake in pigmented tissue by 
homogenous isotopic exchange i.e. when a radioactive iodine atom 
exchanges for a non radioactive one. In the 7-iodoquinoline deriva-
tives exchange was found to occur only slowly at room temperature but 
was brought about more rapidly on heating. The exchange between 
the iodoquinoline derivative and radioiodine supplied as sodium iodide 
was ultimately carried out in a high boiling solvent, ethylene glycol, 
at about 170°. 4-(3-Dimethylaminopropylamino)-7-iodoquinoline can 24 be labelled in this way and specific activities of 3 mCi per rr̂  
18 
to about 100 mCi per rrM have been reported. In contrast this 
method was unsuccessful for 4-(3-dimethylaminopropoxy)-7-iodoquinoline 
and 4-(4-methylpentoxy)-7-iodoquinoline due to decomposition of the 
compounds. Isotopic exchange took place only in 3-dimethylamino-
1-propanol and 4-methyl-l-pentanol solutions respectively, i.e. in 
the alcohol which in each case corresponds to the 4 position side 
chain. 
There are a variety of routes besides isotopic exchange by means 
of which iodine can be introduced into organic molecules. The 
principal methods employed fall into the categories listed below : 
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(a) addition across a double bond e.g. the preparation 
of 1,2 diiodoethane from ethylene, 
(b) reaction of an alcohol with either hydriodic acid or 49 
phosphorus and iodine e.g. the preparation of ethyl iodide 
from ethanol, 
(c) direct iodination with molecular iodine^^, e.g. the 
preparation of 3-iodotyrosine from tyrosine. It should 
be noted that a maximum of only half the iodine can be 
incorporated into the labelled compound by this reaction, 
(d) iodination with iodine chloride^^ e.g. the preparation of 
4,5-diiodofluorescein from fluorescein, 
(e) replacement of a primary aromatic amine through the 52 
Sandmeyer reaction e.g. the preparation of iodobenzene 
from aniline, 
(f) mercuration with mercuric chloride followed by replacement 
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with iodide e.g. the preparation of (4-chloro-2-iodo 
phenoxy) acetic acid from (4-chloro-2-(chloromercuri 
phenoxy)acetic acid, 
(g) heterogenous isotopic exchange where radioiodine exchanges 54 with another halogen in the molecule e.g. the preparation 
of iodoacetic acid from chloracetic acid. 
The advantage in methods (a) and (g) above is due to the specific 
activity of the labelled product corresponding to that of the radio 
iodine used in the labelling. The same control over the specific 
activity of the radioactive material obtained by isotopic exchange 
cannot be exercised because it depends on the extent to which 
radioactive atoms have exchanged with non radioactive ones. Some 
success in the preparation of labelled quinoline derivatives by isotopic 
exchange had been achieved and, since this approach relies on 
established procedures to prepare the non-radioactive compounds e.g. 
by the Skraup reaction, the only limitation would arise from failure 
to prepare the compound to be labelled. On the other hand hetero-
genous exchange has not been reported in the literature for the 
preparation of iodoquinoline derivatives but replacement of an 
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amino group through the Sandmeyer reaction has been carried out e.g. 
the preparation of 5-chloro and 5-bromoquinoline (although not for the 
preparation of radioiodine labelled compounds). There is no 
restriction on the accessibility of quinoline ring positions by this 
method since there are standard methods available to prepare all 
aminoquinolines. The potential value of the Sandmeyer for the 55 
present investigation lay in its reported use for the conversion 
of 4,6-diaminoquinoline to 4-amino-6-halogenoquinoline, from which 
it is evident that the 4-amino group in this diaminoquinoline resists 
diazotisation. The other methods of labelling cannot be applied to 
prepare quinoline derivatives labelled in any desired position since 
the iodination procedures with either molecular iodine or iodine 
chloride, which depend on electrophilic substitution, are limited 
to the susceptible positions, e.g. 3-iodo-4-hydroxyquinoline from 
4-hydroxyquinoline and 5-iodo-8-hydroxyquinoline from 8-hydroxy-
quinoline by treatment with iodine chloride.^^ 
AIMS AND APPROACH 
Although the selective concentration in melanotic tissue of 
some 4-amino-X-iodoquinoline derivatives has been described^^ and 
2 5 
some features of the selectivity have been examined more closely 
most attention has been given to the clinical applications of the 
labelled compounds. For a better understanding of the structural 
requirements to be met in quinoline derivatives to obtain selectivity 
a number of questions remain to be answered, namely : 
(i) Is a substituent group and especially a basic group 
necessary in the 4 position for selective uptake by 
melanotic tissue? 
(ii) What is the difference in uptake between a compound with 
a primary amino group and a compound with a secondary 
amino group in the 4 position? 
(iii) Is the selective uptake of 4-amino-X-iodoquinoline by 
melanotic tissue affected by having the iodo group in the 
5 or 6 positions instead of in the 7 position? 
(iv) Does the degree of selectivity depend on the amount of 
labelled compound administered? 
(v) Is the presence of a halogen substituent in the quinoline 
ring necessary for the selective uptake by melanotic 
tissue? 
The aim of this project was to answer the above questions. To 
achieve this purpose it was intended to prepare quinoline derivatives 
labelled with I in the 5, 6 and 7 positions respectively and to 
measure the radioactivity in tissues and organs following administra-
tion to experimental animals. Therefore methods were devised to 
synthesise these compounds through their respective primary amine 
derivatives and to introduce the required amount of radioiodine as 
a final step by a micro Sandmeyer reaction. In the case of the 
4,X-diaminoquinoline derivatives it was intended to rely (with 
subsequent confirmation of this approach) on the reluctance of the 
4-amino group to undergo diazotisation.^^ 
Where the quinoline derivatives contained no halogen similar 
measurements were planned employing the tritium labelled quinoline 
derivatives prepared by decomposition of a hydrazino group when the 
active protons had been exchanged: with tritium. Several known routes 
leading to the preparation of amino and hydrazino quinoline derivatives 
were compared and, in the course of this work, a number of compounds 
not previously described in the literature were prepared. 
RESULTS AND DISCUSSION 
A. PREPARATION OF QUINOLINE DERIVATIVES 
In order to prepare the required quinoline derivatives into 
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which I could be introduced by the Sandmeyer reaction the 
synthetic programme commenced with the preparation of primary 
aminoquinoline derivatives. 
(i) Monoaminoquinoline Derivatives 
Monoaminoquinoline are conveniently prepared by reduction of 
the respective nitroquinolines which are usually obtained by standard 
methods. By the Skraup reaction 6-nitroquinoline was prepared from 
4-nitroaniline and 5-nitroquinoline from 3-nitroaniline when 7-nitro-
quinoline was produced as a by-product. The yield of 7-nitroquinoline 29 
from this preparation was less than the reported one but was in 
agreement with the different ratio of 5-nitroquinoline:7-nitro-
quinoline (5:1) found in the present work. The alternative method 
of preparing 5-nitroquinoline i.e. by nitration of quinoline, also 
results in a mixture of isomers (8-nitroquinoline is the by-product^^). 
However the latter reaction was preferred because it took place more 
rapidly and more cleanly thatn the former method so the product was 
easier to isolate although the yield was not significantly greater. 
A number of methods are available for the subsequent reduction 58 of the nitro to the amino group e.g. iron with chloride ions or 
59,60,61 ^ , T . , 60,61,62,63,64,65 , , acetic acid, stannous chloride, hydrazine 
with Raney nickel,^^ hydrogen with Raney n i c k e l , p a l l a d i u m 
catalyst in acid,^^ and alcoholic solution^^ or Adams catalyst.^^ 
In early experiments 5-nitroquinoline was reduced with iron powder 
and 6-nitroquinoline with either stannous chloride or iron and acetic 
acid in low hields ( 6 1 7 o , 5 6 7 o and 6 6 7 o respectively). In all cases 
the low yields were attributed to difficulty in recovering the amino-
quinolines from the reaction mixture containing high concentrations 
of metal ions. Subsequently catalytic hydrogénation was found 
to give the most facile reductions of the nitroquinolines in high 
yields (about 9 0 7 o ) and with the advantage that the progress of the 
reaction was indicated by the consumption of hydrogen. By reductions 
carried out in this way 5,6 and 7-aminoquinolines were readily obtained 
in high purity but since they are susceptible to decomposition in 
air and sunlight refrigerated storage in sealed containers was 
necessary to maintain the purity. If this precaution is neglected 
the adverse effect of impurities results in reduced yields of 
labelled compound from the Sandmeyer reaction, 
(ii) 4-Aminoquinoline Derivatives 
The preparation of 4,X-diaminoquinoline derivatives (X = 5, 6 
or 7) was planned because the X-amino group can be replaced selectively 
1 3 1 
with a I labelled iodo group through the Sandmeyer reaction while 
the 4-amino group is resistant to diazotisation. Since 4-amino-
quinoline derivatives can be obtained by the reaction of the 
corresponding 4-chloroquinoline derivatives with ammonia or a primary 
amine it was intended to synthesise the diaminoquinolines from the 
respective 4-chloro-X-nitroquinolines and to reduce the nitro group 
at an appropriate stage of the preparation. With a view to preparing 
I labelled compounds by isotopic exchange as well it was planned 
to synthesise the 4-amino-X-iodoquinoline derivatives (X = 5, 6 
or 7). They can be readily prepared from the respective 4-chloro-X-
iodoquinolines because the 4-halogeno group is preferentially replaced 
by reaction with ammonia or amines while the X-halogeno group is not. 
Consequently the initial steps in the synthesis were directed towards 
the preparation of the 4-chloro-X-iodoquinolines. 
(a) 4-Chloroquinoline Derivatives 
Initially the preparation of the 4-chloroquinoline derivatives 
was attempted from the corresponding quinoline derivatives by the 
introduction of a chloro group in the 4 position following selective 
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nitration of the N-oxide in this position. This route WHS 
selected because it was believed to be the best method of general 
application to any quinoline derivative whereas other methods led 
either to mixtures of isomers in some cases or did not result in the 
5-substituted quinoline derivatives e.g. ethoxymethylene malonic ester 
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method. The scheme outlined in Fig.3b was followed in which the 
appropriate quinoline derivative (14) was oxidised to the N-oxide (15) 
from which the 4-nitroquinoline-l-oxide derivative (19) was obtained 
by selective nitration. The 4-chloroquinoline derivative (16) was 
formed on reduction with phosphorus trichloride. The experimental 
conditions selected for the reactions were the ones claimed in the 
literature to be successful under most circumstances e.g. peracetic 
acid^^ was preferred to monoperphthalic acid for the oxidation of 
quinoline derivatives to the N-oxides because of the reported failure 
FIG. 4a. COURTAULD ATOMIC MODEL OF 4-NITRO-5-IODOQUINOLINE 
FIG. 4b. COURTAULD ATOMIC MODEL OF 4-CHLORO-5-IODOQUINOLINE 
to obtain 8-nitroquinoline-l-oxide by the latter reagent. In 
addition it was found necessary to isolate the crude 4-chloroquinoline 
derivative by precipitation of the free base instead of the recommended 
solvent extraction technique^^ because the extraction characteristics 
of the substituted quinolines were poor. 
The synthesis of the 5-nitro,6-nitro and 7-nitro derivatives of 
4-chloroquinoline was accomplished by this method but the final 
step in the preparation of 4"Chloro-5-iodoquinoline failed to produce 
the required compound. In this case treatment of 4-nitro-5-iodo-
quinoline-l-oxide with phosphorus trichloride only reduced the N-oxide 
function (i.e. without replacement of the 4-nitro group), and resulted 
in 4-nitro-5-iodoquinoline. Since the previously attempted prepara-
tion of 4-chloro-5-iodoquinoline had failed due to the formation of a 
halogen free product when 2-carbethoxy-3-methyl-4-hydroxy-5-iodo-
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quinoline was hydrolysed it was clear that the synthesis of some 
peri substituted 5-iodoquinoline derivatives was impeded. Further 
evidence of this can be seen (Fig.4a and 4b) from Courtauld atomic 
models of 4-nitro-5-iodoquinoline and 4-chloro-5-iodoquinoline. 
Because deformation of the quinoline ring is necessary to accommodate 
the steric configuration of 4-nitro-5-iodoquinoline then considerably 
greater deformation is required for 4-chloro-5-iodoquinoline. In 
view of the steric difficulties synthesis of this latter compound 
by standard methods is unlikely to be successful. 
TABLE 1 
ALTERNATIVE PREPARATIVE ROUTES TO 4,5-DINITROQUINOLINE-l-OXIDE FROM QUINOLINE 
Product Yield (%) Product Yield (7o) 
5-Nitroquinoline 45 Quinoline-1-oxide 90 
5-Nitroquinoline-l-oxide 74 4-Nitroquinoline-l-oxide 60 
4,5-Dinitroquinoline-l-oxide 64 4,5-Dinitroquinoline-l-oxide 50 
Overall yield 21 Overall yield 27 
u> 
Ln 
Whilst this preparative route did lead to the required 4-chloro-
X-nitroquinolines, shortcomings were apparent in the synthesis of 
individual compounds. In the preparation of 4-chloro-5-nitroquinoline 
improvements can be brought about by a change in the order of reactions 
(Table 1). Instead of following the sequence of reactions leading 
from quinoline to 4,5-dinitroquinoline, quinoline-l-oxide was prepared 
first then nitrated in the 4 position before introduction of the 
5-nitro group. In another example an improved yield ( 6 8 7 o ) of 
6-nitroquinoline-l-oxide has been obtained by oxidation of 6-nitro-
quinoline with monoperphthalic acid^^ instead of peracetic acid; the 
latter gives low yields ( 2 7 7 o ) due to the formation of by products 
reported to be 6-nitro carbostyril and its N-oxide.^^ 
In spite of the successful preparations achieved by this route 
it cannot be regarded as a satisfactory approach to the synthesis of 
the 6-nitro and 7-nitro derivatives of 4-chloroquinoline because the 
overall yields of these compounds from the respective nitroanilines 
were exceptionally low (Table 2). Consequently an alternative route 
was sought to prepare these 4-chloroquinoline derivatives and the 
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ethoxymethylene malonic ester method of Price and Roberts (Fig.3d) 
was selected. This method forms the 7 substituted quinolines almost 
exclusively from meta substituted anilines. Since 4-chloro-5-
nitroquinoline had already been satisfactorily prepared by the first 
route this offered a particular advantage over quinoline synthesis by 
the Skraup reaction and the Conrad Limpach method where 5 substituted 
TABLE 2 
COMPARISON OF THE YIELD OF 4-CHLORO-6-NITROQUINOLINE AND 4-CHLORO-7-NITROQUINOLINE 
FROM 4-NITROANILINE AND 3-NITROANILINE 
Initial Compound 4-nitroaniline 3-nitroaniline 
Reaction Product Yield (7o) Product Yield (7o) 
Skraup reaction 6-Nitroquinoline 54 7-Nitroquinoline 10 
Oxidation (acetic acid-
peroxide) 
6-nitroquinoline-
1-oxide 
27 7-Nitroquinoline-l-
oxide 49 
Nitration 4,6-dinitroquinoline-
l-oxide 
32 4,7-Dinitroquinoline-
l-o xLde 
46 
Reduction &. replacement 
of 4-nitro-group 
4-chloro-6-nitro-
quinoline 
72 4-chloro-7-nitro 
quinoline 
85 
Overall Yield 3.4 1.9 
O J 
quinoline constitutes a major proportion of the product. 
The scheme followed is shown in Fig. 5 where 3-nitroaniline (29) 
is condensed with diethyl ethoxymethylene malonate (25) and the 
resulting acrylate (30) cyclised to 3-carbethoxy-4-hydroxy-7-
nitroquinoline (31). Hydrolysis of this ester followed by thermal 
decarboxylation produced 4-hydroxy-7-nitroquinoline (34) which was 
converted to the 4-chloro derivative (35) in the usual way. It was 
anticipated that the overall yield of 4-chloro-7-nitroquinoline would 
be low when prepared by this method since it depended on the 
decarboxylation of the 3-carboxy-4-hydroxy derivative (32). This 
prediction is based on the fact that the preparation of 4-chloro-
6-nitroquinoline described in the literature^^ gave little better 
than nominal yields of 4-hydroxy-6-nitroquinoline by decarboxylation. 
By first converting the acid to its silver salt (33), improved yields 
in the thermal decarboxylation of the 3-carboxy-4-hydroxyquinoline 
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derivative were obtained and by employing this technique the poor 
( -<107o) yield of 4-hydroxy-7-nitroquinoline (34) was lifted to 547o. 
The low yields encountered in the preparation of 4-chloro-6-iodo and 
4-chloro-7-iodo quinoline by this method occurred on decarboxylation 
of 3-carboxy-4-hydroxy-6- and 7-iodoquinolines. However they were 
comparable with those previously reported in the literature^^ and may 
be due to decomposition with the release of iodine vapour. 
(b) Introduction of the Amino Group into the 4 Position 
The formation of derivatives of 4-aminoquinoline from the 
4-chloroquinoline derivatives already synthesised by replacement of 
N O 0 
(29) 
c(COOC2H5)2 
+ C H 
NH2 I 
O C 2 H 5 
(25) 
c i c O O C z H s ) 
2"5 
(33) 
NOâ QIQ 
(34) 
CI 
N O oTo N 
(35) 
FIG. 5 PREPARATION OF 4-CHLORO-7-NITROQUINOLINE BY THE DIETHYLETHOXYMETHYLENE 
MALONATE METHOD. 
the chloro group occurred readily with ammonia. This was achieved 
in all cases in phenol solution and usually at refluxing temperature 
( 1 7 0 - 1 8 0 ° ) except in the case of 4-chloro-5-nitroquinoline when below 
average yields were obtained under these conditions. If, however, 
the reaction was carried out at a lower temperature ( 1 4 0 - 1 5 0 ° ) the 
yield of 4-amino-5-nitroquinoline increased to above 7 0 7 o . 
Where a secondary amino group with a particular side chain was 
required in the 4 position an excess of the appropriate primary amine 
was reacted with the 4-chloroquinoline derivative. 4-(3-Dimethyl-
aminopropylamino)-7-nitroquinoline was easily obtained from 4-chloro-
7-nitroquinoline in this way but the similar reaction of 4-chloro-
6-iodo and 4-chloro-7-iodoquinoline with 3-dimethylaminopropylamine 
did not proceed as readily and a more intensive purification was 
required to remove starting material from the product. 
(c) Preparation of 4,X-Diaminoquinoline Derivatives 
Two approaches were considered to prepare the 4,X-diaminoquinoline 
derivatives from the 4-chloro-X-nitroquinolines. In the first one it 
was intended to reduce the X-nitro group to the amino group before 
introducing the second amino group at the 4 position. However the 
initial experiments to reduce the nitro group by a number of methods 
proved unsuccessful, e.g. hydrogénation with palladium catalyst 
resulted not only in reduction but also in dehalogenation. It ĵ as 
clear that this approach had not taken the reactivity of the 4-chloro 
group into account; therefore reduction of the nitro group without 
removal of the chloro group was unlikely to be successful. 
Consequently the alternative method, i.e. replacing the chloro 
group by the amino group before reduction of the nitro group, was 
attempted. It was intended to employ stannous chloride for the 
reduction of the nitro group in the 4-amino-X-nitroquinoline 
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derivative because of its reported application for this purpose. 
The preparation of 4,6 diaminoquinoline and 4,7-diaminoquinoline 
derivatives by this method met with immediate success but 4-amino-
5-nitroquinoline was not reduced to 4,5-diaminoquinoline. However 
hydrogénation over palladium with acetic acid as solvent gave the 
mono acetate salt of 4,5-diaminoquinoline which after sintering above 
100° finally melted at 172-173°. The infra red spectrum of the salt 
showed absorptions at 2900, 1620, 1540 and 1400 cm"^ which were 
indicative of protonated amine and carboxylate ion. In the n.m.r. 
spectrum of the salt there was a three proton singlet atôl.93 
(MeCOO ) and a broad signal of five protons at Ô8.0 which disappeared 
on exchange with deuterium oxide. The aromatic proton signals were 
present as two doublets (J = 6.5 Hz) atô8.82 andô6.65 (H2 and H3), 
a quartet = 7.0 and 1.5 Hz) atô6.94 (H8) and a two proton multiplet 
at 57.1-7.7. On warming the acetate salt in the probe of the mass 
spectrometer, a strong signal at '̂ /e 60 (CH^COOH) was generated and 
on further heating a strong signal ^/e 159 (4,5-diaminoquinoline parent 
ion) appeared. 
(iii) Replacement of an Amino Group through Diazotisation 
(a) Preparation of Hydrazinoquinoline 
Hydrazinoquinolines offer the most suitable method for the 
introduction of tritium in a specific location on the quinoline ring. 
Diazotisation of a primary amine followed by reduction of the diazo-
74 75 
nium salt produces the hydrazino derivatives ' which after exchange 
of the active protons decomposes to the tritium compound. The 
hydrazino derivatives of 4-aminoquinoline were prepared in this way 
by taking advantage of the resistance to diazotisation shown by the 
4-amino group in 4,X-diaminoquinolines e.g. 4-amino-6-hydrazino-
quinoline was prepared from 4,6-diaminoquinoline in this way. 
(b) Preparation of lodoquinoline Derivatives through 
the Sandmeyer Reaction 
Aryl diazonium salts react rapidly with iodide (or ) ions 
in mineral acid solution to form the corresponding iodo compound,^^ 
Although this reaction is classified as a Sandmeyer reaction it does 
not require cuprous iodide to facilitate this replacement. This 
method is particularly useful when employed to prepare the iodo-
quinolines from the respective monoaminoquinolines since the products 
are steam volatile and so are capable of isolation in high purity. 
5-iodo and 6-iodoquinoline which are well known solids were prepared 
by this route in addition to 7-iodoquinoline which is an oil at room 
temperature and is not as well characterised^^ e.g. the hydrochloride 
isolated here is not reported in the literature. 
Since diazotisation of 4,6-diaminoquinoline is known to take place 
preferentially at the 6-amino group a similar preference on the part 
of 4,5-diaminoquinoline and 4,7-diaminoquinoline was expected to allow 
the selective introduction of the iodo group into the 5 and the 7 
positions as well. In fact, by using reagents in equimolar proportions 
to reduce the possibility of reaction by the second amino group, 4-amino-
7-iodoquinoline respectively 4-(3-diinethylaminopropylamino)-7-iodo-
quinoline were formed from the corresponding 7-aminoquinoline derivatives 
in good yields. However, unlike the 6-amino and 7-amino compounds, no 
iodoquinoline could be extracted from the basified solution following 
the diazotisation of 4,5-diaminoquinoline and subsequent treatment with 
potassium iodide. When the solution was adjusted to pH 6.5 a precipitate 
was obtained; this was soluble both in acid and in alkali, which 
suggested that one of the amino groups had been replaced by a hydroxyl 
group to give a hydroxy quinoline derivative. This can be explained 
by successful competition of water against the bulky iodide ion - a 
consequence of steric hindrance in the peri position - in the nucleophilic 
substitution reaction. 
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(c) Preparation of I Labelled Iodoquinoline Derivatives 
131 
The use of I to prepare labelled quinoline derivatives introduced 
a number of problems not normally encountered in preparative organic 
chemistry. Because of the high radiotoxicity of this nuclide, 
special precautions must be employed to avoid ingestion of the compounds. 
131 As I emits gamma and hard beta radiation the chemical techniques are restricted to those which can be carried out by remote handling methods. 
131 
To minimise the hazards it is desirable to introduce the I, if 
possible, as the last step in the preparation sequence. Even though 
this process may lead to employing chemically inefficient procedures 
for the preparation of the labelled material, nevertheless it had been 
^^^Te (B,r) ''^e P — (T, 2 x 10^ years) 
2 
^^^Te (n,r) ^^^Te P — (T, 8 days) 
Fig.6 NUCLEAR REACTIONS LEADING TO THE FORMATION 
131 OF I, STABLE AND LONG LIVED NUCLIDES OF IODINE. 
accepted from the very beginning that safety was paramount to other 
considerations. 
It has already been demonstrated in this work that the required 
iodoquinoline derivatives can be prepared by replacing an amino group 
through the Sandmeyer reaction with non-radioactive iodide. In order 
to prepare labelled compounds with a controlled high specific activity 
131 
It was necessary to know accurately the specific activity of the I 
solution to be used in the Sandmeyer reaction. It is often assumed 
that radioiodine solutions contain only iodine corresponding to the 131 
radioactive nuclide (which for I is about 8 |ig per Curie). However 
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the I available for this work contained iodine from other sources, 
in particular as an impurity in materials and reagents employed in the 
chemical separation of this nuclide and as a result of certain nuclear 131 
reactions also occuring during the reactor production of I (see Fig.6.). 
Consequently a number of micro methods reported for the determination 
of iodine concentrations^^'^^'^^ were tested. From the concentration 131 
of iodine determined in I solutions (about 300 |ig/ml for a range of 
concentrations from 100 to 1000 mCi/ml) it can be seen that the lowest 
specific activity is 42 mCi per |i Equiv. of iodine. As it was intended 
to use these radioiodine solutions in the preparation of moniodo-
quinoline derivatives of 5 mCi per |iM specific activity it was neces-
sary to add the appropriate quantity of potassium iodide carrier to 
each radioiodine solution to lower its specific activity to 5 mCi per [i 
Equiv. By use of the radioiodine solutions the labelled iodoquinolines 
and the 4-amino-iodoquinoline derivatives were readily obtained through 
TABLE 3 
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RADIOCHEMICAL PURITY OF I LABELLED QUINOLINE DERIVATIVES. 
(Sterile solutions of 5 mCi/(iM specific activity at room temperature) 
Quinoline Derivative 
Time after 
Labelling 
(days) 
5-Iodo 6-Iodo 7-Iodo 
4-Amino-
-6-Iodo 
4-Amino-
-7-Iodo 
4- ( 3-dimethylamino-
propylamino)-7-Iodo 
131 7o of I in required chemical form 
0 99 99 99 89 90 -
1 - - 99 92 90 89 
3 96 - - - - -
4 - - 98 - - -
5 94 - - 88 - -
-o 
the Sandmeyer reaction on the 5 M-M scale. Although the former compounds 
could be isolated by steam distillation, separation of the latter ones 
was more difficult. Ultimately they were isolated by extraction into 
chloroform. 
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With the exception of the rather labile 5-iodoquinoline- I which 
showed progressive breakdown over a number of days, the autoclaved 
solutions of the iodoquinolines were almost radiochemically pure (Table 3) 
On the other hand the radiochemical purity of the 4-amino-X-iodoquinoline 
derivatives was not as high as could be desired, although they were 
stable in solution at room temperature showing no evidence of breakdown 
on storage. The low values found for the radiochemical purity of the 
labelled 4-amino-X-iodoquinoline may be attributable to the characteris-
tics of the analytical method employed. A modified t.l.c. procedure 
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based on reported chromatographic methods ' gave excellent separations 
of the many quinoline derivatives both from each other and also from 
iodide ions. However, the 4-amino-X-iodoquinolines were not separated 
from iodide as satisfactorily as the iodoquinolines and the small 
tailing of radioactivity found could not be assigned unambiguously. 
This tailing and the contribution from the breakdown of the more 
sensitive amino compounds on the highly active surface was responsible 
for the apparently low radiochemical purity. 
(iv) Radioactive Labelling by Exchange 
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(a) I Labelled Compounds 
In contrast to the Sandmeyer reaction where the specific activity 
of the labelled compound is controlled by adjusting the specific 
activity of the radioiodine used to replace the primary amino group, 
labelling by exchange is limited by the rate of the exchange reaction. 
When the exchange reaches equilibrium i.e. when there is a uniform 
.J-. . . ^ Z radioiodine - , , 
specific activity of ^ iodine both product and reactants, 
the maximum specific activity of the product is attained. If isotopic 
exchange occurs too readily, the lability of the radioactive group 
would lead to rapid loss of a substantial proportion of the label in 
the biological system. In the case of 4-(3-dimethylaminopropylamino)-
131 
7-iodoquinoline, exchange of the 7-iodo group with I iodide took 
place only slowly even in a high boiling solvent such as ethylene 
glycol. This homogeneous isotopic exchange is described by the 
equation: 
RI + R^^^I + I 
where RI represents 4-(3-dimethylaminopropylamino)-7-iodoquinoline. 
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According to the kinetic treatment of Wahl and Bonner and that of 
83 Charlton 
R ^^^ I J a 
R b L 
RI 
131^- . RI 
if the exchange reaction was carried out for a set period and, except 
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for the specific activity of I, under fixed conditions on two 
occasions (a'and'b*). 131 
In the present work, the initial quantity of RI was 100 mg and R I 
is about 0.1 |ig in each case, therefore the concentration of RI can 
be considered unchanged from the initial value i.e. [ RI_ RI Jb 
The values for the other quantities on each occasion were: 
a b 
131 
R I 8 mCi 6 mCi 
131 -I 17 mCi 144 mCi 
l" 15 fig 180 fig 
Substitution of the above values in the equation shows that the 
131 
amounts of I incorporated into the labelled compound on each 
occasion are consistent with each other. Furthermore the second 
labelling attempt 'b' illustrates the weakness of the exchange method: 131 
when a greatly increased quantity of I (150 mCi) was used, in 
contrast to 25 mCi used the first time, less radioiodine was incorporated 
into the compound. Under the particular conditions employed, a higher 
specific activity product could only be obtained if higher specific 
131 activity I were used in the exchange. 
Once it has been shown that a compound can be labelled with 
131 
I by homogeneous isotopic exchange then heterogeneous isotopic 
exchange of the radioactive iodo group with e.g. chloride ions, can 
be expected to take place also. This would result in the loss of the 
radioactive label. The rate at which the latter exchange proceeds is 
particularly important in the case of radioactive labelled quinoline 
derivatives for parenteral injection as solutions of these compounds 
also containing sodium chloride are sterilised by autoclaving. This 131 was demonstrated by autoclaving a solution of I labelled 4-(3-
dimethylaminopropylamino)-7-iodoquinoline (i) in citric acid when no 
131 increase was found in I in the form of free iodide and (ii) in 
hydrochloric or sulphuric acids where there was an increase on auto-
131 claving in the proportion of I exchanged. The reason for this is 
the absence of exchangeable ions from the citric acid solutions. In 
all cases where additional chloride ions had been added much larger 
131 
portions of I were exchanged. The significance of this result is 
that labelled quinolines for testing in experimental animals must be 
prepared in solutions containing non exchangeable ions if they are to 
be sterilised by autoclaving. The distribution of radioactivity 
determined experimentally in the animal body will not represent 
accurately the distribution of the labelled compound if a significant 131 
proportion of the I in the administered material is in the form of 
131 
iodide ions. I labelled quinolines which required sterilisation 
by autoclaving prior to injection into animals, were formulated in an 
acetate buffer solution containing no halogen anions. 
It had been anticipated that iodide ions could be removed from 
solutions of labelled quinolines by absorption on anion exchange resin. 131 In fact, a single passage of I labelled 4-(3-dimethylaminopropylamino) 
-7-iodoquinoline in citric acid solution through a column of ion exchange 
131 
resin lowered the proportion of I as iodide ions from 9 7 o to 4.57» and 
five passages to less than O . 5 7 o . However, while this procedure can be 
employed to improve the radiochemical purity of solutions to be given 
orally, anion exchange resins have been found to be a source of 
pyrogenic material and solutions treated with them may not be injected 
parenterally unless tested for apyrogenicity by the standard British 
Pharmacopoeia method. 
(b) H Labelled Compounds 
Quinoline derivatives labelled in the benzene ring were prepared, 
by an isotopic exchange method, from the hydrazinoquinoline derivative 
in which the hydrazino group is decomposed after the exchange of the 
active protons. This procedure has the advantage of introducing the 
tritium label at a specific position on the quinoline ring. Alter-
native methods for the labelling of quinolinederivatives reported in 
84 
the literature have relied either on electrophilic tritiation in 
hot sulphuric acid solution, tritiation by exposure to tritium gas 
(Wilzbach method) or on catalytic dehalogenation of a halogenoquinoline 
derivative with tritium gas. However the exchange methods have been 
84 
reported to introduce tritium in all the susceptible positions on 
the quinoline ring and result in a compound labelled in a number of 
positions. Catalytic dehalogenation can clearly be used to introduce 
tritium into a selected position by replacement of a halogeno group 
but experimental details and the results obtained have not been 
described therefore the value of the method cannot be adequately 
assessed. 3 Initially it was attempted to prepare 4-aminoquinoline-6- H from 
4-amino-6-hydrazinoquinoline but only nominal yields were obtained so 
3 
instead quinoline-5- H was prepared from 5-hydrazinoquinoline. 
3 3 4-Aminoquinoline-5- H was synthesised from the quinoline-5- H through 
quinoline-l-oxide, its 4-nitro derivative and 4-chloroquinoline. 
This method was chosen because the conditions normally used for the 
catalytic reduction of 4-nitroquinoline-l-oxide to 4-aminoquinoline 
are conducive to catalytic isotopic exchange and therefore result 
in loss of the tritium label. 
(v) Correlation of Spectral Data 
Infra Red Spectra 
Confirmation of the presence of functional groups and establish-
ing the identity of the products from microscale preparations was 
predominantly carried out by comparison of the infra red spectra of 
the quinoline derivatives with the spectra obtained from authentic 
specimens. Comparisons were made with a number of absorption 
frequencies published previously for nitroquinolines, for halogeno-
quinolines^^, and for a wide range of 4-substituted quinolines^^ and 
with assignments of the ring stretch bands and the in plane and out 
of plane CH deformation frequencies published for monosubstituted 
87 
quinolines. While the 4-, 5-, 6-, and 7- monosubstituted quinolines 
display ring stretching absorptions which correlate well, in the range 
1630-1550 cm with the published values there is no similar correlation 
either in the 1500-1350 cm ^ region or for the in plane and out of 
plane frequencies at 1300-800 cm All the absorption frequencies 87 
reported for monosubstituted quinoline derivatives were present 
in the compounds examined. However not all the frequencies were 
identified in every compound. This was attributable to the difficulty 
in detecting low intensity absorptions. 
One feature emerging from an examination of the infrared spectra 
of the 4,X-disubstituted quinoline derivatives and their N-oxides is 
a relationship between the X position and the absorption frequencies 
at about 800 cm The 4,5 disubstituted derivatives have two 
prominent absorption peaks between 850 cm ^ and 810 cm the 
4,7 derivatives absorb at about 830 cm ^ with a stronger absorption 
frequency at about 800 cm while the 4,6 substituted ones absorb 
at one of the latter two frequencies. In the few 4,6 substituted 
compounds absorbing at both 800 and 830 cm"^ it was the 800 cm"^ band 
which had the lower intensity. Although the number of compounds 
studied is not large, these differences may give a method of 
distinguishing between 4,6 and 4,7 substituted quinolines. 
In a spectral investigation published previously strong 
absorption in both the 1350 cm ^ and the 1190 cm ^ regions was 
86 
attributed to the N-oxide function in quinolines. All the 
quinoline-l-oxide derivatives examined in this work (Table 4) 
absorbed (in addition to bands characteristic of the functional 
group) both in the 1190 cm ^ region and in the 1350 cm ^ region 
but the band at 1190 cm ^ was neither particularly prominent nor 
was it unique to the N-oxides. Although the individual frequencies 
of the N-oxides may be related in a systematic way to substitution 
in particular positions, too few compounds were studied here to 
permit definite assignment of any of the individual peaks to a 
particular pattern of substituents. 
TABLE 4 
PROMINENT ABSORPTION FREQUENCIES OF QUINOLINE AND DERIVATIVES 
650 - 900 cm -1 
Quinoline 730m 752w 777m 796s 
5-Nitroquinoline 712w 728m 767m 788m 800m 835m 886m 
7-NitroquinoIine 720m 753m 777w 787s 825m 875m 885w 
4-Aminoquinoline 716s 747m 774w 800vw 820w 877w 
5-Aminoquino1ine 702m 720w 760m 770s 803m 850w 870w 
6-Aminoquinoline 715w 755m 820s 830s 
7-Aminoquinoline 715w 755m 779w 824s 846s 
5-IodoquinoIine 727m 750vw 792s 828w 878m 
7-Iodoquinoline hydrochloride 720w 757m 840s 870w 
Quino1ine-1-oxide 768m 790m 875s 
5-Nitroquinoline-l-oxide 715s 735m 762w 777w 865w 
7-Nitroquinoline-l-oxide 718w 728m 755s 810s 873m 
5-Iodoquinoline-l-oxide 735m 770w 775s 
4,5-Dinitroquinoline-l-oxide 716w 735m 753m 775s 825m 837m 
4,6-Dinitroquinoline-l-oxide 715w 737m 762vw 788s 846s 856s 
4,7-Dinitroquinoline-l-oxide 724m 764m 790s 825w 845m 865m 
4-Chloro-5-nitroquinoline 700w 715w 750m 813s 833m 
4-Chloro-6-nitroquinoline 675w 716w 735m 797m 810w 847s 896s 
4-Chloro-6-iodoquinoline 670m 713m 760w 820m 835s 867m 
4> 
TABLE 4 (contd.) 
4-Chloro-7-nitroquinoline 675w 715w 735s 800m 825m 845m 
4-ChIoro-7-iodoquinoline 670m 720wb 760m 805s 835w 840m 855s 875s 
4-Amino-5-nitroquinoline 725m 750m 813w 827s 845m 
4-Amino-6-nitroquinoline 716vw 740s 795w 830s 877w 895w 
4,6-Diaminoquinoline 720m 774m 827m 886w 
4,7-Diaminoquino1 ine 677m 725m 767w 806s 823w 857s 
4-Amino-6-iodoquinoLine 653w 717s 763m 820s 880w 
4-Amino-7-iodoquinoline 715m 757w 801m 825w 865w 875w 883w 
4- ( 3-Dimethy Lamino-propy 
amino)-7-aminoquino1ine 
65 3w 697vw 744m 763vw 778w 813vw 843m 
4-(3-DimethyLamino-propyl-
amino)-7-iodoquino1 ine 
717w 767m 793m 813w 838w 850w 870w 
3-Carboxy-4-hydroxy-6-
iodoquinoline 
720w 740w 750w 787m 828s 880w 897w 
5-Hydrazinoquinoline dihydro-
chloride 
688m 720vw 740vw 792s 890m 
4-Amino-6-hydrazinoquinoLine 
dihydrochloride 
668vw 690w 738w 765vw 
900 
795w 
- 1200 
830m 
-1 cm 
850m 
QuinoLine 929m 1025m 1110m 1135W 
5-Nitroquinoline 945m 965w 986w 1024w 1067m 1120m 1135W 
7-Nitroquinoline 932w 974w 1008m 1053m lllOw 1124w 
4-Aminoquinoline 936w 964m 1013w 1072w 1143m 1160m 
5-Aminoquinoline 929w 993w 1030m 1060m 1185W 
v-n Ln 
TABLE 4 (contd.) 
6-Aminoquinoline 902m 955m 1115m 1140m 1154w 
7-Aminoquinoline 913w 964m 1033w 1102w 1140m 1177w 
5-Iodoquinoline 942w L044vw 1070VW 1135m 1190W 
7-Iodoquinoline hydrochloride 938s 1030W 1045m 1140W 1153m 1198m 
Quinoline-1-oxide 967w 978w 1050m 1091s 1135m 1145m 1186m 
5-Nitroquinoline-l-oxide 927w 955m 978m lOOOw 1013w 1057w 1125W 1198w 
7-Nitroquinoline-1-oxide 910w 978m 1029m 1070m 1128w 1190m 
5-Iodoquinoline-l-oxide 1062w 1114w 1189m 
4,5-Dinitroquinoline-1-oxide 902w 95 3w 978w 987w 1070W 1097w 1135W 1159w 1190m 
4,6-Dinitroquinoline-l-oxide 900w 960vw 99 3w 105 3w 1094w 1159m 1179m 
4,7-Dinitroquinoline-1-oxide 902vw 917m 987w 1037w 1097w 1140m 1160W 1180W 
4-Chloro-5-nitroquinoline 924w 975m 1068w 1143w 1190m 
4-Chloro-6-nitroquinoline 980m 1083m 1130VW 
4-Chloro-6-iodoquinoline 957w 970m 1040W 1175s 
4-Chloro-7-nitroquinoline 904m 917w 973w 1050w 1075W 1135W 1183m 
4-Chloro-7-iodoquinoline 963s 1050m 1063w 1140w 1180w 1190W 
4-Amino-5-nitroquinoline 968w 1068vw 1144vw 1190VW 
4-Amino-6-nitroquinoline 907w 1007w 1080m 1130m 1140W 
4,6-Diaminoquinoline 1090W 1143m 
4,7-Diaminoquinoline 946m 1013w 1090W 1117m 1165W 1172w 
4-Amino-6-iodoquinoline 908w 930mb 970mb 1007wb 1065W 1095VW 1130W 1145wb 1165wb 
4-Amino-7-iodoquinoline 910wb 930wb 1015W 1050VW 1097vw 1115W ll50wb 1190m 
Ĉ  
TABLE 4 (contd. ) 
4-(3-Dimethylaminopropyl-
amino)-7-aminoquino1ine 
940vw 948w 978w 1030m 1060VW 1090W 1125VW 1150m 1171m 
4-(3-DimethyLaminopropyl-
amino)-7-iodoquino1ine 
900w 965vw 992w 1035W 1075W 1090W 1130m 1160W 1190w 
3-Carboxy-4-hydroxy-6-iodo-
quinoline 
918m 930m 1115W ll53w 1187m 
5-Hydraz inoquinoline 
dihydrochloride 
983m 1094w 1160W 
4-Amino-6-hydrazinoquinoline 
dihydrochloride 940m 1045W 1103vw 1135m 1160m 1170m 
1200 - 1600 -1 cm 
Quinoline 1317m 1365m 1385m 1425m 1465W 1495VS 1565m 1595m 
5-Nitroquinoline 1330m 1340m 1358m 1490w 15l2w 1595W 
7-Nitroquinoline 1322m 1478w 1525s 1570W 
4-Aminoquinoline 1300m 1337m 1510m 1560W 1578m 
5-Aminoquinoline 1260m 1305W 1395W 1488w 1558m 1574m 1599m 
6-Aminoquino1ine 1230W 1276m 1330W 1416w 149 7mb 1513m 
7-Aminoquinoline 1210m 1290m 1316s 1365m 1500s 1558m 1588m 
5-Iodoquinoline 1210W 1315m 1330m 1425m 1492m 1515s 1550w 
7-Iodoquinoline 
hydrochloride 1220W 1303m 1558w 1885m 1593m 
Quinoline-1-oxide 1202s 1225m 1260s 1310m 1340w 1396m 1515s 1578s 
5-Nitroquinoline-l-oxide 1253m 1286m 1310m 1335s 1360s 1500m 1525m 
7-Nitroquinoline-l-oxide 1255m 1300m 1336s 1355s 1420s 1497m 1518m 1528m 1570m 
TABLE 4 (contd.) 
5-Iodoquinoline-l-oxide 1253s 1290W 1337S 1524s 1553w 1560m 
4,5-Dinitroquinoline-l-oxide 1250W 1297S 1330S 1344s 1355S 1494vw 1505W 1525S 1558w 
4,6-Dinitroquinoline-l-oxide 1250m 1285S 1297S 1320S 1343m 1515m 1540S 1565W 
4,7-Dinitroquinoline-l-oxide 1297S 1322m 1338m 1396m 1498m 1528m 1575m 1595m 
4-Chloro-5-nitroquinoline 1210W 1299w 1407W 1490m 1528mb 1575m 
4-Chloro-6-nitroquinoline 1288m 1338m 1415W 1517m 1567m 1587w 
4-Chloro-6-iodoquinoline 1270W 1325m 1337m 1480m 1545m 1560m 
4-Chloro-7-nitroquinoline 1234w 1288vw 1340m 1415W 1515sb 1580m 
4-Chloro-7-iodoquinoline 1280m 1288m 1340W 1408w 1478m 1545S 1574m 1595S 
4-Amino-5-nitrequinoline 1275m 1322m 1347W 1427w 1570S 
4-Amino-6-nitrequinoline 1218vw 1280S 1323s 1340m 1495S 1557VW 1597S 
4,5-Diaminoquinoline-
monacetate 1540S 
4,6-Diaminoquinoline 1225W 1247w 1285W 1335m 1413VW 1477m 1505W 1575m 
4,7-Diaminoquinoline 1230m 1295S 1328m 1390m 1515S 1540W 1580sb 
4-Amino-6-iodoquinoline 1210W 1275W 1300W 1495m l'537vw 1555m 1575m 
4-Amino-7-iodoquinoline 1275m 1323VW 1346vw 1505VW 1565W 1570S 1595m 
4-(3-Dimethylaminopropyl-
amino)-7-aminoquino1 ine 1230m 1270VW 1306m 1330m 1370W 1440m 1415m 1495W 1540W 1575S 
4- ( 3-Dimethylaniinopropy lamine 
7-iodoquinoline 1234w 1250W 1280W 1327w 1403vw 1537VW 1583sb 
3-Carboxy-4-hydroxy-6-
iodoquinoline 1250W 1280W 1340W 1362w 1505VW 1525VW 1565m 
5-Hydraz inoquinoline 
dihydrochloride 1235W 1280W 1310m 1420W 1570wb 1595mb 
TABLE 4 (contd.) 
4-Amino-6-hydrazinoquinoline 
dihydrochloride 
Quinoline 
5-Nitroquinoline 
7-Nitroquinoline 
4-AminoquinoLine 
5-Aminoquino1ine 
6-Aminoquino1ine 
7-Aminoquino1ine 
5-Iodoquinoline 
7-Iodoquinoline hydro-
chloride 
Quinoline-l-o xLde 
5-Nitroquinoline-L-oxide 
7-Nitroquinoline-L-oxide 
5-Iodoquinoline-l-oxide 
4.5-DinitroquinoLine-
1-oxide 
4.6-Dinitroquinoline-
l-oxide 
4.7-Dinitroquinoline-l-
oxide 
4-Chloro-5-nitroquinoline 
1214s 1237s 1275W 
1604m 1627m 
1605wb 1650VW 
1620w 
1626w 1655m 1720w 
1610m 1655m 
1625m 1645m 
1600W 1623s 1645m 
1600m 1880wb 1960wb 2340 -
1650mb 
1650mb 
1608m 1630W 
1615W 
1625vw 
1296w 
1600 - 4000 cm 
1421w 
-1 
1480sb I500sb 
1605m 1623w 
1625W 
2950-
2700mb 
3060W 
3070m 
3120wb 
3140 - 3300vwb 
3300 - 3700wb 
3120 - 3280mb 3280 - 3540wb 
3100 3240mb 3240 3340wb 
3120 3230mb 3280 3450wb 
3120 - 3240mb 3240 - 3460mb 
3220 - 3550wb 
3440mb 3500mb 
3100 - 3600mb 
3220 - 3270wb 3350 - 3450mb 
3110W 3140 
3070W 3110w 3130w 
3115W 3153w 
3080w 31lOw 3130VW 
3100VW 3300 - 3530wb 
TABLE 4 (contd. ) 
4-Chloro-6-nitroquinoline 1627m 3090VW 3320 - 3520wb 
4-Chloro-6-iodoquinoline 1630 - 1760wb 1920VW 3740wb 
4-Chloro-7-nitroquinoline 1615W 3100W 3270 - 3650wb 
4-Chloro-7-iodoquinoline 3060VW 3080VW 
4-Amino-5-nitroquinoline 1615W 1635m 1655s 2300 - 2500wb 3180mb 3340mb 3500m 
4-Amino-6-nitroquinoline 1602m 1667s 3150mb 3350wb 3430s 
4,5-Diaminoquinoline mono-
acetate 1620s 
4,6-Diaminoquinoline 1620m 1665m 3220mb 3260 - 3500sb 
4,7-Diaminoquinoline 1623s 1650W 1660m 1900w 3050 - 3260mb 3350s 3370w 3420s 
4-Amino-6-iodoquinoline 1635W 1655s 1715wb 1900VW 2680m 3140wb 3260wb 3350wb 3450m 
4-Amino-7-iodoquinoline 1635W 1655s 1695W 1715W 1900wb 2350wb 3140mb 3340wb 3460m 
4-(3-Dimethylaminopropy1-
amino)-7-aminoquino1ine 1610m 1675W 3100 - 3300wb 3300 - 3700sb 
4-(3-Dimethylaminopropyl-
amino)-7-iodoquino1ine 1620s 2790W 2840W 2960m 3080 - 3280sb 3280 - 3500sb 
3-Carboxy-4-hydroxy-6-
iodoquinoline 1622s 1696s 2680VW 2740VW 3075W 3170W 3220W • 3250W 
5-Hydrazinoquinoline di-
hydrochloride 1640m 1770W 3100 - 3300wb 3320 - 3680wb 
4-Amino-6-hydrazino-
quinoline dihydrochloride 1610sb 1640sb 1900 - 2300wb 3050 - 3160mb 3160 - 3700vsb 
o 
V - very: s - strong: m - medium: w - weak: b - broad: 
TABLE 5 
PERCENTAGE DISTRIBUTION OF ADMINISTERED AS A LABELLED 
lODOQUINOLINE, IN THE BODY AND EXCRETA OF HOODED RATS 
(200g approx) 
5-Iodoquinoline 6-Iodo-
Quinoline 
7-Iodo-
Quinoline 
Time of Sacrifice 
after injection 
(hr) 
24 48 72 96 96 96 
Eyes 0.001 0.003 0.007 0.02 0.002 0.001 
Skin (pigmented) 0.6 0.3 0.9 0.6 0.4 1 
(cpm/g) (30) (20) (30) (20) (10) (3) 
Skin (unpigmented) 0.3 0.4 1 0.5 0.7 0.9 
(cpm/g) (30) (20) (25) (10) (10) (3) 
Blood 0.2 0.06 0.4 0.1 0.01 0.6 
Gut 0.6 0.2 2 0.4 0.5 2 
Heart 0.005 0.01 0.009 0.02 0.007 0.005 
Kidneys 0.08 0.06 0.2 0.07 0.05 0.06 
Liver 0.7 0.5 1 0.6 0.4 0.4 
Lungs 0.03 0.03 0.09 0.02 0.004 0.02 
Spleen 0.01 0.02 0.006 0.01 0.002 0.008 
Stomach 0.2 0.1 0.4 0.1 0.07 0.02 
Residual Carcass 13 11 24 13 15 11 
Excreta 85 87 69 84 83 84 
B. THE DISTRIBUTION OF THE LABELLED MATERIALS IN EXPERIMENTAL ANIMALS 
(i) Monoiodoquinolines 
Most of the radioactivity originating from labelled 5-iodoquinoline 
was excreted from the rat's body within 24 hours. Thereafter, up to 
the last time of measurement at 96 hours after administration, only 
traces appeared both in the faeces and the urine. The same 
distribution of radioactivity was found in rats from either 5-, 6-, or 
7-iodoquinolines (Table 5). Although when administering either 
labelled 6- or 7-iodoquinolines measurements were only made after 96 
hours, it can be safely assumed, by analogy with 5-iodoquinoline, that 
they too were similarly excreted soon after administration. 
Preferential concentration of the radioactivity remaining in 
the body of the rat was not apparent in the pigmented tissues i.e. 
in the eyes and in the coloured skin, at the end of the experimental 
period. The exception was 5-iodoquinoline for which a higher 
concentration of radioactivity was found in pigmented than in non-
pigmented skin (Table 6), indicating some selective affinity for the 
pigmented skin. However, not only did the amount of labelled compound 
behaving in this way represent a small proportion of the initial dose 
but also the concentration of radioactivity in the pigmented skin 
(cpm/g) was low indicating that the monoiodoquinolines display no 
significant affinity for pigmented tissue. 
(ii) lodoaminoquinolines 
131 
Contrary to the initial expectations, the concentration of I 
TABLE 6 
RELATIVE CONCENTRATIONS OF 131 I IN PIGMENTED AND NON PIGMENTED 
SKIN OF RATS 
131 I Labelled Quinoline Period in cpm/g pigmented skin 
animal (hr) cpm/g non pigmented skin 
5-Iodoquinoline 24 1 
48 1 
72 1.2 
96 2 
6-Iodoquinoline 96 1 
7-Iodoquinoline 96 1 
in pigmented skin could not be used for the purposes of comparing 
the diagnostic value of these compounds. The reason for this is the 
variation found in the intensity of skin pigmentation in individual 
animals. While all the animals used in these experiments possessed 
deeply pigmented fur, the poorer skin pigmentation of some was only 
apparent on dissection. Concentration of labelled compounds in the 
pigmented skin was indicative of a biologically active compound but 
incorporation depends more on the degree of pigmentation than on 
differences between the individual compounds, 
(a) In Rats 
The affinity of labelled 4-amino-6-iodoquinoline and 4-amino-
7-iodoquinoline is high^ specific for pigmented tissue. High 
concentrations of radioactivity were measured in the eyes and pigmented 
131 
skin (Table 7) and the total amounts of I in these tissues represent 
a significant proportion of the dose of labelled compound administered. 
Almost all the radioactive material not incorporated into the pigmented 
tissue was excreted by the rats. This indicates that the introduction 
of the primary amino group into the 4 position of either 6- or 7-iodo-
quinoline is responsible for the acquisition of the biological activity 18 
It has been reported previously that two thirds of the excreted 
radioactivity (which is, on average, ITL of the total dose) appeared 
in the urine following oral administration to humans of a single dose 
of radioiodine labelled 4-(3-dimethylaminopropylamino)-7-iodoquinoline 
although the nature of the radioactive compound excreted was not 
established. By contrast little radioactivity was found in the 
TABLE 7 
131 I DISTRIBUTION IN ORGANS AND CONCENTRATION IN TISSUES IN 
HOODED RATS (200g approx) SACRIFICED AFTER 96 HOURS 
Labelled Quinoline 4-Amino-6-iodoquinoline 
Route of Administration intra peritoneal Oral 
Dose of Quinoline |iM 
administered |LiCi 
0.01 0 .01 
50 25 
7o tissue 
conc. 
(cpm/g) 
7o tissue 
conc. 
(cpm/g) 
Eyes 2. 5 2x10^ 0. 3 
4 2x10 
Skin (Pigmented) 2 4x10^ 0. 2 5x10^ 
Skin (Non Pigmented) 0. 6 2 3x10 0. 4 4x10^ 
Muscle n. d. 10^ n. d. 5x10^ 
Blood 0. 02 3x10^ 0. 008 2x10^ 
G.I.T. 0. 5 n.d. 0. 2 n.d. 
Heart 0. 02 5x10^ 0. 004 3x10^ 
Kidneys 0. 2 2x10^ 0. .02 4x10^ 
Liver 0. 4 10^ 0. 09 4x10^ 
Lungs 0. 03 6x10^^ 0. 01 2x10^ 
Spleen 0. 05 2x10^ 0. ,005 2x10^ 
Fat n. d. n.d. n. ,d. 20 
Residual Carcass 0. 9 n.d. 0, ,7 n.d. 
Excreta 90 n.d. 98 n.d. 
n.d. = not determined: 
G.I.T. = Gastrointestinal Tract 
TABLE 7 (contd.) 
4-Amino-7-iodoquinoline 
Oral intra peritoneal oral 
O.OA 0. Ol 0. ,01 0.04 
100 50 25 100 
7o tissue 
conc. 
(cpm/g) 
7o tissue 
conc. 
(cpm/g) 
7o tissue 
conc. 
(cpm/g) 
7o tissue 
conc. 
(cpm/g) 
0.4 1x10^ 2 2x10^ 0.3 4 2x10 0.6 2x10^ 
0.2 4 4x10 2 5x10^ 1 8x10^ 0.2 3x10^ 
0.2 2x10^ 3 2x10^ 2 2x10^ 0.2 4x10^ 
n.d. n.d. 3x10^ n.d. 3x10^ n.d 10^ 
O.Ol 4x10^ 0.3 2x10^ 0.04 8x10^ O.Ol 5x10^ 
0.2 n.d. 1 n.d. 0.7 n.d. 0.2 n.d. 
0.001 2x10^ 0.03 6x10^ O.Ol 2x10^ 0.003 5x10^ 
0.02 7x10^ 0.1 2x10^ 0.05 8x10^ 0.02 8x10^ 
0.07 9x10^ 0.7 3x10^ 0.4 2x10^ 0.2 4x10^ 
0.009 5x10^ 0.06 10^ 0.02 5x10^ 0.008 6x10^ 
0.002 3x10^ O.Ol 9x10^ O.Ol 3x10^ 0.001 4x10^ 
n.d. 40 n.d. n.d. n.d. 90 n.d. 
0.5 n.d. 5 n.d. 4 n.d. 1 n.d. 
n.d. n.d. 86 n.d. 92 n.d. n.d. n.d. 
urine of rats following administration of either 4-amino-6-iodoquinoline 
or 4-amino-7-iodoquinoline. Both radioiodine labelled iodoquine and 
4-(3-dimethylaminopropylamino)-7-iodoquinoline are known to be 
incorporated into pigmented tissue independently of the route of 
administration, i.e. whether they were given orally or parenterally. 
It has not, however, been previously determined whether the efficiency 
of incorporation is rel ated to the route of administration. In this 
work the uptake of the iodoaminoquinolines in pigmented tissue was 
shown to be 8 times higher when administered by intraperitoneal injection 
than when given orally (Table 7). Since it is unlikely that such a 
great dependence on the route of administration would have been over-
looked in the clinical trials reported,^^'^^ these results suggest 
that compounds with an unsubstituted 4-amino group follow a different 
metabolic path than those with certain secondary amino groups in the 
4-position. 
It is well known that chloroquine is degraded in the human body 
when given orally.^^ Although the nature of the degradation products 
is not fully known, there is de-ethylation to the corresponding 
secondary amine, 4-(4-ethylamino-l-methylbutylamino)-7-chloroquinoline, 
which is excreted in the urine.^^ Obviously derivatives of 4-amino-
quinoline possessing only a primary amino group cannot undergo this mode 
of degradation. As the metabolic pathways of the two groups of 
compounds differ, it is not surprising to find excretion taking place 
88 
mainly by different routes. It has been proposed that, 
4-(3-dimethylaminopropylamino)-7-iodoquinoline combines with glucuronide 
in the liver and is concentrated in melanomas by the action of tumour 
glucuronidase. In order to establish whether the metabolism of the 
labelled iodoaminoquinolines fits this proposal or, at least, to derive 
information concerning the metabolic pathway followed, the progress 
of the radioactivity through the body of the rat was monitored by 
means of a gamma camera. 
This technique showed, following oral administration of the 
compounds, that : 
(i) after 8 hours the radioactivity was concentrated in the liver 
(with smaller amounts in the thyroid and the upper 
gastrointestinal tract) 
(ii) after 24 hours at least three quarters of the amount had 
been excreted and the residue was mainly concentrated in the 
intestines with traces in the thyroid, eyes and liver 
(iii) after 96 hours the residual radioactivity in the rat was 
concentrated in the eyes and in the thyroid (with traces 
only in the liver). 
It was clear that the labelled compound which was absorbed from 
the gastrointestinal tract was metabolised in the liver and, confirming 
the finding earlier in this work, was predominantly excreted in the 
faeces. Whilst this evidence is consistent with some form of metabolism 
in the liver it does not provide detailed evidence of the pathway by 
which the radioactive material becomes incorporated in pigmented tissue, 
(b) In Tumour Bearing Mice 
The metabolic fate of labelled 4-amino-6-iodoquinoline and 4-amino-
-7-iodoquinoline in tumour bearing animals was the same as observed 
TABLE 8 
I DISTRIBUTION IN ORGANS AND CONCENTRATION IN TISSUES IN 
C-57 MICE WITH MELANOMAS 
Labelled Quinoline 4-•Amino-6-iodoquinoline 
Route of Administration intra peritoneal oral 
No. of Mice in Group 3 2 
7o tissue 
conc. 
(cpm/g) 
7o tissue 
conc. 
(cpm/g) 
Melanoma 3 4x10̂ ^ 0.5 4x10^ 
Eyes 1 3x10^ 0.1 4x10^ 
Skin (Pigmented) n.d. 6x10^ n.d. 4x10^ 
10^ Muscle n.d. 2x10 n.d. 
Blood 0.005 2x10^ 0.001 60 
Bone n.d. 10^ n.d. 50 
G.I.T. 0.07 n.d. 0.04 n.d. 
Heart 0.07 7x10^ 0.001 50 
Kidneys 0.03 10^ 0.002 10^ 
2x10^ Liver 0.09 10^ 0.02 
Lungs 0.006 4x10^ 0.003 2x10^ 
Spleen 0.004 4x10^ 0.001 40 
Fat n.d. 4x10^ n.d. 10^ 
Residual Carcass 2 n.d. 1 n.d. 
n.d. = not determined 
G.I.T. = Gastrointestinal Tract 
Percentage distribution values are percentages of administered dose; 
The remaining radioactivity is contained in the excreta which could 
not be collected. 
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Each mouse given 10 |LiCi of I labelled compound at a specific 
activity of 5 mCi/|j,M and sacrificed after 96 hours. 
TABLE 8 (contd.) 
4-Amino-7-iodoquinoline 4-(3-dimethyiaminopropyia iodoQuinoline 
mino-/-
intra peritoneal oral intra peritoneal oral 
3 2 5 1 
7o tissue 7o tissue 7o tissue % tissue 
conc. 
(cpm/g) 
conc. 
(cpm/g) 
conc. 
(cpm/g) 
conc. 
(cpm/g) 
0.5 4 3x10 0.1 4x10^ 0.5 4x10^ 0.05 4 2x10 
1 3x10^ 0.5 4 3x10 0.4 4 2x10 0.1 4 2x10 
n.d. 9x10^ n.d. 3x10^ n.d. 2x10^ n.d. 3x10^ 
n.d. 7x10^ n.d. 10^ n.d. 80 n.d. 60 
0.03 10^ 0.004 2x10^ 0.02 2x10^ n.d. 10^ 
n.d. 10^ n.d. 80 n.d. 2x10^ n.d. 2x10^ 
0.4 n. d. 0.06 n.d. 2 n.d. 0.5 n.d. 
0.008 8x10^ 0.001 2x10^ 0.04 6x10^ 0.007 4x10^ 
0.03 10^ 0.004 2x10^ 0.1 8x10^ 0.03 7x10^ 
0.3 4x10^ 0.1 2x10^ 0.7 0.2 7x10^ 
0.02 10^ 0.003 2x10^ 0.04 6x10^ O.Ol 5x10^ 
0.006 7x10^ 0.001 80 0.05 6x10^ 0.004 3x10^ 
n.d. 2x10^ n.d. 10^ n.d. 5x10^ n.d. 30 
5 n.d. 0.5 n.d. 1 n.d. 1 n.d. 
in healthy rats except that the radioactivity was concentrated not only 
in the skin and eyes but also in the melanomas. Furthermore, in 
agreement with the previous results in rats, the compounds administered 
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parenterally resulted in an 8 times higher concentration of I in 
the eyes and melanomas than after oral administration. Contrary to 
this, the pattern of the uptake of 4-(3-dimethylaminopropylamino)-7-
iodoquinoline features higher concentrations in the melanomas following 
oral administration (Table 8). As it is unlikely that the metabolic 
pathway is species dependent, the difference in biological effect 
observed with substitution of the 4-amino group must be attributed 
to the structural features of the molecule. 
It has been reported that the 6 and 7 positions of 4-(3-dimethyl-
aminopropylamino)-quinoline are equivalent for substitution by an iodo 
group. In fact, similar results were found for the incorporation of 
radioactivity from 4-amino-6-iodoquinoline and 4-amino-7-iodoquinoline 
into the eyes of rats and mice and for the distribution in other tissues 
Table 8 shows that a five times higher proportion of the initial dose 
of the 6-iodo compound accumulated in melanomas but this is simply 
due to the presence of larger tumours in those animals. The 
affinities of these compounds for the tumours, as represented by the 
concentration of is about equal confirming that, for substitution 
by an iodo group, the 6 and 7 positions of 4-aminoquinoline are also 
equivalent. 
Lt could have been anticipated that either the affinity for 
pigmented tissue or the rate of metabolism of the labelled compounds 
would depend on the quantity of the quinoline derivative administered. 
f. . -.... • . • ' 
FIG.7a GAMMA CAMERA DISPLAY OF MOUSE 96 HOURS AFTER A 30 ̂ iCi 
ORAL DOSE OF 4-(3-DIMETHYLAMINOPROPYLAMINO)-7-IODOQUINOLINE-131 
^ » 
t# 
FIG.7b ABOVE MOUSE PARTIALLY DISSECTED TO SHOW THE LOCATION OF THE 
MELANOMA 
TABLE 9 
EFFECT OF SPECIFIC ACTIVITY ON TISSUE CONCENTRATIONS OF 
RADIOIODINE FROM 4-(3-DIMETHYLAMINOPROPYLAMINO)-7-IODO-
QUINOLINE 
IN C-57 MICE WITH B16 MELANOMA 
10 |iCi of compound was administered to each mouse by i.p 
injection. All mice sacrificed after 96 hours 
Dose of Compound (|iM) 3 0.002 
Specific Activity of 
Compound mCi/mM 3.2 5,000 
Radioactive nuclide 125x 131i 
cpm/g 
Melanoma 4 8x10 4x10^ 
Eyes 5x10^ 2x10^ 
Skin 2x10^ 2x10^ 
Muscle 10^ 80 
Blood 2x10^ 2x10^ 
Bone n.d. 2x10^ 
Heart 5x10^ 6x10^ 
Kidneys 5x10^ 8x10^ 
Liver 
Lungs 
/ 
6x10^ 
r\ 
Spleen 6x10 
Fat 3x10^ 5x10^ 
The amount of radioactivity given to each animal in this work was the 
same as had been used to obtain the results previously r e p o r t e d . ^ ^ 
However the specific activity of the compounds prepared here was much 
higher than those previously available. Therefore the actual quantity 
of the quinoline derivative administered to each animal was considerably 
131 smaller. Compari son of the concentratioiB of I in tissue reported 
24 
in this work with published results obtained with low specific 
activity 4-(3-dimethylaminopropylamino)-7-iodoquinoline showed that, 
in fact, there is a dose dependence. Less of the high specific 
activity material employed here was found in all tissues, both in 
pigmented and in non-pigmented ones, (Table 9). However, it is just 
as easy to distinguish between melanotic tumours and non pigmented 
tissues in this case as with large doses of low specific activity 
material. This is demonstrated by the gamma camera oscilloscope display 
(Fig.7a) where the melanoma is clearly differentiated from all other 
tissues. The same partially dissected mouse is also shown (Fig.7b) 
to indicate the correlation between the radioactivity and the location 
of the tumour. 3 (iii) 4-Aminoquinoline-5- H 
This work has shown that the presence of a primary amino group 
in the quinoline ring causes the labelled compounds to concentrate 
in the eyes. However, only slightly higher concentrations of radio-
activity were found in the eyes than in other tissues following the 
administration of tritium labelled 4-aminoquinoline, i.e. a quinoline 
derivative without a halogen substituent (Table 10). The concentrations 
TABLE 10 
H CONCENTRATIONS IN TISSUES IN C-57 MICE WITH MELANOMAS 
GIVEN 4-AMINOQUINOLINE-5- H 
Sacrificed after 96 hours 
Dose of Compound (fiM) 0.3 0.6 
cpm/mg 
Melanoma 2x10^ 40 
Eyes 4x10^ 10^ 
Skin 4x10^ 10^ 
Muscle 4x10^ 3x10^ 
Blood n.d. 3x10^ 
Bone 3x10^ 20 
Heart 2x10^ 3x10^ 
Kidneys 2x10^ 10^ 
Liver 3x10^ 10^ 
Lungs 2x10^ 80 
Spleen 5x10^ 4x10^ 
Fat 5x10^ 4x10^ 
of tritium measured in the implanted melanomas were less than in many 
non pigmented tissues. It is e/ident therefore, that in order to 
achieve the selective affinity for melanotic tumours and pigmented 
tissues, the presence of a halogen substituent is necessary in the 
benzene ring of the quinoline ring system. 
C. IMPLICATIONS OF THE RESULTS 
The outstanding feature common to the 4-aminoiodoquinoline derivatives 
is their highly selective affinity for pigmented tissue. From the 
point of view of ease of preparation the labelled compound that can be 
given orally has two main advantages: 
(i) it does not have to be completely apyrogenic as does a 
solution for parenteral administration 
(ii) a smaller amount of radioactive material is concentrated in the 
eyes when the compound is given orally. 
The most successful compound given orally was 4-(3-dimethylamino-
propylamino)-7-iodoquinoline. Its ability to concentrate in pigmented 
tissue is similar to that shown by 4-amino-7-iodoquinoline when given 
by injection. However, without clinical assessment, it is not clear 
how the diagnostic value is affected by the difference in the routes 
of elimination from the body of the two types of compounds. Never-
theless, whichever compound is preferred by the physician it can be 
readily prepared by the method developed in this project namely, by 
means of the Sandmeyer reaction from the corresponding primary amine. 
In addition, the specific activity of the compound can be adjusted to any 
desired value. 
The clinical implications of the availability of labelled compounds 
with high specific activity are based on the rapid excretion of the 
radioactive material from the body when only small amounts of quinoline 
derivatives (35 \ig per kg body weight) are administered. The most 
important condition, the ability to differentiate pigmented tissues from 
TABLE 11 
CALCULATED RADIATION DOSE RECEIVED BY THE EYE FROM 
VARIOUS IODINE NUCLIDES UNIFORMLY DISTRIBUTED IN 
THE IRIS AND CHOROID ASSUMING RETENTION FOR THE PERIOD 
OF TOTAL DECAY OF THE NUCLIDE 
Nuclide 123^ 125^ 131^ 
Half Life 13 hour 60 days 8 days 
Eye Radiation Dose 
rads/fiCi 0.03 2 3 
non pigmented ones, is not adversely affected - and may even be slightly 
enhanced - under these conditions. Consequently a patient would 
receive a smaller radiation dose because of the more rapid clearance 
of radioactivity from the body. It may even be possible to scan 
effectively before the 5 day delay period used in current practice. 
It is known that the critical organ in the body exposed to 
radiation originating from the radioiodine labelled quinoline derivatives 
is the eye. The actual radiation dose received depends both on the 
particular radioiodine nuclide employed and on the period it is resident 
89 
in the eye. The calculations made of the dose received by the eye 
from various iodine nuclides assuming (for the purposes of the 
calculation) that the radioactivity remained in the eye for the whole 
period of total decay of the nuclide are reported in Table 11. 125 
Obviously some I could be released before even one half life has 
elapsed. The actual radiation dose would therefore be less than the 
calculated one although there is insufficient information at present 
to predict the extent by which it would be reduced. 
It can also be seen that an even lower radiation dose can be 123 
achieved by the use of I in melanoma diagnosis. Formerly this 
would not have been considered possible. But, because labelling with 
radioiodine through the Sandmeyer reaction is a facile procedure, the 123 
use of this nuclide is now feasible because the I labelled compound 
can be prepared immediately before use. In addition it is likely 
that scanning too may be carried out earlier before excessive decay 
of the nuclide has occurred by using material with high specific 
activity. Unfortunately I is produced by means of a high energy 
charged particle accelerator, e.g. a cyclotron, and is not yet readily 
accessible in Australia. However, elsewhere in the world the potential 
application of this nuclide merits thorough examination. 
EXPERIMENTAL 
1. GENERAL 
Elemental Microanalyses 
Microanalyses for carbon, hydrogen and nitrogen were carried out 
by the Australian Microanalytical Service, CSIRO, Melbourne. 
Melting Points 
Melting points were determined in capillaries on the Buchi 
apparatus and are uncorrected. 
Infra Red Spectra 
The infra red absorption spectra of solid compounds were obtained 
in nujol mull on a Perkin Elmer Model 237 spectrometer. The spectra 
of liquid compounds were obtained in a liquid film sample. 
Nuclear Magnetic Resonance Spectra 
Proton magnetic resonance spectra were obtained on a Varian A60 
machine at the University of New South Wales. Samples were prepared 
as 107o W/V solutions in hexadeuterodimethyl sulphoxide and chemical 
shifts (5) are quoted in ppm downfield from tetramethyl silane 
( 6 = 0.000) as an internal reference. 
2. METHODS 
Thin Layer Chromatography 
The progress of all reactions were monitored by thin layer 
chromatography and qualitative visual assessments were made of the 
relative proportions of products, by products and reactants. The 
radiochemical purity of each labelled compound was determined by 
measurement of the distribution of radioactivity along the thin layer 
chromatogram. Excellent separations of almost all the substituted 
quinolines involved in this work were obtained on 100 |im layers of 
silica gel with fluorescent indicator (Eastman sheet 6060) developed 
with 2 5 7 o V/V triethylamine in chloroform and visualised with U . V . light. 
131 3 
Determination of I and H 
131 
The absolute rad ioactivity of I in samples was measured by 
determination of the ionisation current from the sample in a calibrated 
4 TT gamma ionisation chamber or in the Nuclear Chicago Mediae dose 
calibrator. 
The relative radioactivity of animal tissue specimens containing 
131 
I was determined by counting each specimen at a fixed low geometry 
from a Nuclear Chicago gamma scintillation counter. The relative 
131 
concentrations in tissue of I were determined by counting 50-100 mg 
tissue specimens in a well-crystal gamma scintillation counter. The 
131 
distribution of I along thin layer chromatograms was determined by 
counting each chromatogram divided into 5 mm sections in a well crystal 
gamma scintillation counter. 131 
Determinations of the iodine concentrations in I solutions at 
100 to 1000 mCi/ml were carried out by the bleaching of ferric thio-
cyanate colour. 3 
The absolute activity of H in labelled compounds was determined 
3 
by liquid scintillation counting with the addition of H internal 
standard for calibration. The relative radioactivity of animal organs 
o 3 
containing H was not measured. The relative concentrations of H 
in tissue specimens were determined by dissolving 50-100 mg tissue samples 
in Nuclear Chicago N.C.S. reagent then adding liquid scintillator and 
counting in an Ansitron liquid scintillation spectrometer. Corrections 
3 for quenching were made by the addition of 0.1|.lCi of H to each vial 
3 
and recounting. The distribution of H along thin layer chromatograms 
was determined by liquid scintillation counting of the chromatogram 
divided into 5 mm sections each of which was added to liquid scintil-
lator in a counting vial. 
3. PREPARATION OF QUINOLINE DERIVATIVES 
A. Mononitroquinolines 
(i) 5-Nitroquinoline 
(a) 5-Nitroquinoline was prepared in 5 0 7 o yield (together 
with 7-nitroquinoline (c.f. (iii)) from 3-nitroaniline by the Skraup 
reaction^^ m.p. 70° (lit.^^ 71°). (Found: C, 61.8; H, 3.6; N, 16.0. 
Calc. for C^H^N^O^: C, 62.0; H, 3.5; N, 16.1%). 
(b) 5-Nitroquinoline, prepared in 4 5 7 o yield by the direct 
nitration of q u i n o l i n e h a d m.p. 70-71° and was identical with the 
above material. 
(ii) 6-Nitroquinoline 
6-Nitroquinoline was prepared in 547» yield from 4-nitroaniline by 
the Skraup reaction^^'^^ m.p. 149° (lit.^^ 148-149°). (Found: C, 61.9; 
H, 3.6; N, 16.1. Gale, for C^H^N^O^: C, 62.0; H, 3.5; N, 16.1%). 
(iii) 7-Nitroquinoline 
7-Nitroquinoline was prepared in 107» yield [ together with 
5-nitroquinoline (c.f. (i)a) ] from 3-nitroaniline by the Skraup 
reaction^^ m.p. 134° (lit.^^ 136°). (Found: C, 61.9; H, 3.5; N, 15.9. 
Calc. for C^H^N.O.: C, 62.0; H, 3.5; N, 16.1%). V o Z Z 
B. Monoaminoquinolines 
(i) 4-Aininoquinoline 
4-Aminoquinoline monohydrate was prepared in 6 3 7 o yield from 
4-chloroquinoline (c.f. C (i)) by reaction with ammonia in boiling 
73 5 ̂  phenol m.p. 67-68° (lit. 67°). (Found: C, 66.3; H, 6.0; N, 17.3. 
Calc. for C^HgN^. H^O: C, 66.6; H, 6.2; N, 17.3%). On drying 
anhydrous 4-aminoquinoline of m.p. 152.5-153.5° (lit.^^ 154-155°) 
was obtained. (Found: C, 74.7; H, 5.6; N, 19.4. Calc. for C^H^N,: 
9 o 2 
C, 75.0; H, 5.6; N, 19.4%). 5 8.40, 6.70 (2H, 2d, J 5.2 Hz; H2 and H3), 
6.83 (2H, s; NH^). 
(ii) 5-Aminoquinoline 
(a) 5-Aminoquinoline was prepared in 95% yield from 5-
nitroquinoline (c.f. A (i)) by catalytic reduction in glacial acetic 
acid solution with hydrogen at atmospheric pressure and 1.5 to 2% of 
the 5-nitroquinoline weight of palladium at a concentration of 5% on 
barium sulphate m.p. 110-110.5° (lit.^^ 108-110°). (Found: C, 75.3; 
H, 5.6; N, 19.1. Calc. for C^H^N^: C, 75.0; H, 5.6; N, 19.4%). 
5 8.82 (IH, 2d, J 4.1 Hz, J. , 1.7 Hz; H2), 7.40 (IH, 2d, J_ _4.1 HzJ^ , 
8.6 Hz; H3), 7.26 (IH, m; H4), 6.81 (IH, 2d, J, ^ 7.1 Hz, J^ ^ 1.7 Hz; —O , / —D , O 
H6), 7.50 (IH, 2d, ¿^ ^ 7.1 Hz, J^ g 8.3 Hz; H7), 8.57 (IH, m; H8), 
5.95 (2H, s; - NH^). 
(b) 5-Aminoquinoline was prepared in 617o yield from 
5-nitroquinoline by reduction with iron powder in the presence of 
58 o 
chloride ions m.p. 103-105 , undepressed on admixture with the above 
material. 
o 
(iii) 6-Aminoquinoline 
(a) 6-Aminoquinoline was prepared in 917o yield from 
6-nitroquinoline (c.f. A (ii)) by catalytic reduction as for 
5-Aminoquinoline m . p . 113-114.5° (lit.^^'^^ 114°). (Found: C, 75.1; 
H , 5.7; N , 19.2. Calc. for C^HgN^: C, 75.0; H , 5.6; N , 19.4%). 
(b) 6-Aminoquinoline was prepared in 567» yield from 
6-nitroquinoline by reduction with iron and acetic acid^^'^^ 108-110 
and identical with the above material. 
(c) 6-Aminoquinoline was prepared in 6 6 7 o yield from 
6-nitroquinoline by reduction with stannous chloride in hydrochloric 
acid^^'^^ m . p . 110-112° and identical with the above material. 
(iv) 7-Aminoquinoline 
7-Aminoquinoline dihydrate was prepared in 8 8 7 o yield from 
7-nitroquinoline (c.f. A (iii)) by catalytic reduction as for 
5-aminoquinoline m . p . 71.5-72.5° (lit.^^'^^ 74-75.5°). On drying 
o 57 94 o 
anhydrous 7-aminoquinoline was obtained m.p. 91-92 (lit. ' 93.5-94 ). 
(Found: C, 74.7; H, 5.8; N , 19.8. Calc. for C^HgN^: C, 75.0; H, 5.6; 
N , 1 9 . 4 7 o ) . 8 . 6 9 ( I H , 2 d , J ^ 3 4 . 3 H z J ^ ^ ^ 1 . 8 H z ; H 2 ) , 7 . 1 1 ( I H , 2 d , 
Hz,2 8.2 Hz; H3) 8.05 (IH, m; H4), 7.73 (IH, m; H5), 7.20 (IH, 2d, J^^^ 
3,4 ' 
9.4 Hz, ^ o 2.5 Hz; H6) 7.21 (IH, m; H8), 5.75 (2H, s;NH ). 
—o ,0 ^ 
C. Monohalogenoquinolines 
(i) 4-Chloroquinoline 
4-Chloroquinoline was prepared as an oil in 8 9 7 o yield from 
4-nitroquinoline-l-oxide (c.f. G (i)) by reaction with phosphorous 
trichloride in chloroform.^^ The crude product was not purified but 
was used directly in the preparation of 4-aminoquinoline. 
(ii) 5-Iodoquinoline 
5-Iodoquinoline was prepared in 8 9 7 o yield from 5-aminoquinoline 
f» B (ii)) by the Sandmeyer reaction, using 5-aininoquinoline which 
had been further purified by a double precipitation of the hydrochloride 
from ether. The product was isolated by steam distillation m.p. 
102-103° (lit.^^ 104-105°). (Found: C, 42.2; H, 2.4; N, 5.3. Gale, 
for C^H^IN: C, 42.4; H, 2.4; N, 5.5%). 
(iii) 6-Iodoquinoline 
(a) 6-Iodoquinoline was prepared in 2 7 7 o yield from 
6-aminoquinoline (c.f. B (iii)) by the Sandmeyer reaction as for 
5-iodoquinoline m.p. 83-84° (lit.^^ 88°). (Found: C,42.3; H, 2.5 ; 
N, 5.5 . Gale, for G^H^IN: G, 42.4; H, 2.4; N, 5.5%). 
(b) 6-Iodoquinoline was prepared in 2 0 7 o yield from 
4-iodoaniline by the Skraup reaction m.p. 86.5-88 (lit. 88 ). 
(iv) 7-Iodoquinoline 
7-Iodoquinoline was prepared from 7-aminoquinoline (c.f. B (iv)) 
by the Sandmeyer reaction as for 5-iodoquinoline. The free base from 
30 o 
steam distillation was an oil (lit. b.p. 176-179 /lO mm) from which 
the hydrochloride of 7-iodoquinoline was prepared m.p. 216-217°. 
(Found: G, 37.1; H, 2.5; N, 4.7. G^H^Gl IN requires: C, 37.1; H, 2.4; 
N, 4.8%). 5 9.36 (IH, m; H2), 8.02 (IH, 2d, 5.1 Hz, 8.4 
Hz; H3), 9.20 (IH, m; H4), 8.13-8.18 (2H, m; H5, H6), 8.88 (IH, m; H8). 
D Monohydrazinoquinolines 
(i) 5-Hydrazinoquinolines 
5-Hydrazinoquinoline was prepared from 5-aminoquinoline (cof» B(ii)) 
by diazotisation and reduction of the diazonium compound with stannous 
chloride^^ and isolated in 8 7 7 o yield as the dihydrochloride m.p. 
247-248° (lit.^^ 247°). The free base, 5-hydrazinoquinoline, was 
liberated by sodium hydroxide solution from the above hydrochloride 
m.p. 152-153° (lit.^^ 150-151°). (Found: C, 68.1; H, 5.8; N, 26.1. 
Calc. for C^H^N : C, 67.9; H, 5.7; N, 26.4%). 5 8.83 (IH, 2d, J. . 
z, J 
4.3 Hz, J^^^ 1.8 Hz; H2) 7.35 (IH, 2d, J^ 3 4.3 Hz, J^ ^ 8.6 Hz; H3), 
7.30 (IH, m; H4), 7.09 (IH, 2d, J^ ^ 7.4 Hz, J^ ^ 1.7 Hz; H6), 7.60 
(IH, 2d, 7.4 Hz, J^^g 8.4 Hz; H7) 8.59 (IH, m; H8), 7.67 (IH, s; 
NH), 4.14 (2H, s; NH^). 
E. Quinoline-l-Oxide 
Quinoline-l-Oxide was prepared in 9 0 7 o yield from quinoline by 
oxidation with hydrogen peroxide in glacial acetic acid as described 
O CT 
by Ochiai m.p. 58° (lit. 62°) (Found: C, 73.9;H, 5.1; N, 9.6. Calc. 
for C^H^NO: C, 74.4; H, 4.9; N, 9.7%). 
F. Monohalogenoquinoline-1-oxides 
(i) 5-Iodoquinoline-l-oxide was prepared in 9 0 7 o yield from 
35 
5-iodoquinoline (c.f. C (ii)) as for quinoline-l-oxide above, 
m.p. 159-161°. (Found: C, 39.6; H, 2.2; N, 5.0. C^H^ INO requires: 
C, 39.9; H, 2.2; N, 5 . 2 7 o ) . 68.75 (IH, m; H2), 7.69 (IH, 2d, J^ 3 6.1 
Hz, J3 ^ 9.1 Hz; H3), 8.27 (IH, m; H4), 8.53 (IH, 2d, J^^^ 7.7 Hz, 
J^ g 1.1 Hz; H6) 7.97 (IH, 2d, ̂ ^ ^ 7.7 Hz, J^^g 8.9 Hz; H7), 8.94 
(IH, m; H8). 
G. Mononitroquinoline-l-oxides 
(i) 4-Nitroquinoline-l-oxide 
4-Nitroquinoline-l-oxide was prepared in 6 0 7 o yield by nitration 
o c 
of quinoline-l-oxide (c.f. E) as described by Ochiai m.p. 155-156° 
(lit.^^ 153-154°). (Found: C, 56.6; H, 3.2; N, 14.3. Calc. for 
S " 6 V 3 ' N, 14.7%). 68.75, 8.36 (2H, 2d, J 7.0 
Hz; H2 and H3). 
(ii) 5-Nitroquinoline-l-oxide 
5-Nitroquinoline-l-oxide was prepared in 74% yield from 5-nitro-
quinoline (c.f. A (i)) under the conditions given for the preparation 
of quinoline-l-oxide^^ above,m.p. 136° (lit.^^ 155-157°). (Found: 
C, 56.6; H, 3.2; N, 14.6. Calc. for C^H^N^O^: C, 56.8; H, 3.2; 
N, 14.7%). 
(iv) 7-Nitroquinoline-l-oxide 
7-Nitroquinoline-l-oxide was prepared in 49% yield from 7-nitro-
quinoline (c.f. A (iii)) under the conditions given for the preparation 
of quinoline-l-oxide^^ above, m.p. 178-179° (lit.^^ 174-175°). (Found: 
C, 56.7; H, 3.3; N, 14.6. Calc. for C^H^N^O^: C, 56.8; H, 3.2; 
N, 14.7%). 58.69 (IH, m; H2), 7.64 (IH, 2d, J 5.0 Hz, J . . 8.5 Hz; 
z, J J, 4 
H3), 8.04 (IH, m; H4), 8.33 (2H, m; H5 and H6), 9.15 (IH, m; H8). 
H. Dinitroquinoline-l-oxides 
(i) 4,5-Dinitroquinoline-l-oxide 
4,5-Dinitroquinoline-l-oxide was prepared in 647o yield by the 
nitration of 5-nitroquinoline-l-oxide (c.f. G (ii)) under the conditions 
35 
for the preparation of 4-nitroquinoline-l-oxide above (c.f. G (i)) 
and on recrystallisation from ethanol-dimethylformamide had m.p. 
265-266° dec. (lit.^^ 260-262° dec.). (Found: C, 45.7; H, 2.3; 
N, 17.8. Gale, for C^H^N^O^: C, 46.0; H, 2.2; N, 17.97o). 6 8.95, 
8.48 (2H, 2d, J 6.9 Hz; H2 and H3), 9.00 (IH, 2d, ̂  ^ 8.7 Hz, 
J^^g 1.4 Hz; H6), 8.19 (IH, 2d, J^ ^ 8.7 Hz, J^ ^ 7.9 Hz; H7), 
8.79 (IH, m; H8). 
(ii) 4,6-Dinitroquinoline-l-oxide 
4.6-Dinitroquinoline-l-oxide was prepared in 827o yield by 
nitration of 6-nitroquinoline-l-oxide (c. f. G (iii)) under the 
conditions for the preparation of 4,5-dinitroquinoline-l-oxide above, 
O C 
m.p. 224.5-225.5° dec. (lit. 218° dec.). (Found: C, 45.7; H, 2.2; 
N, 17.8. Gale, for G^H^N^O^: G, 46.0; H, 2.2; N, 17.9%). 58.98, 
8.61 (2H, 2d, J 6.9 Hz; H2 and H3), 9.65 (IH, 2d, J. ^ 2.5 Hz, J^ ̂  —J , / —J , o 
0.8 Hz; H5). 
(iii) 4,7-Dinitroquinoline-l-oxide 
4.7-Dinitroquinoline-l-oxide was prepared in 467» yield by nitration 
of 7-nitroquinoline-l-oxide (c. f. G (iv)) under the conditions for the 
preparation of 4,5-dinitroquinoline-l-oxide above,m.p. 200-201° dec. 
(Found: G, 45.9; H, 2.3; N, 17.6. G^H^N^O^ requires: G, 46.0; H, 2.2; 
N, 17.97o). 6 8.98, 8.61 (2H, 2d, J 7.0 Hz; H2 and H3), 8.99 (IH, 2d, 
J^ ^ 9.5 Hz, J^ g 0.7 Hz; H5), 8.67 (IH, 2d, J^^^ 9.5 Hz, J^^g 2.5 Hz; 
H7)^ 9.23 (IH, d, J^^g 2.5 Hz; H8). 
1. Nitro-halogenoquinoline-l-oxide 
(i) 4-Nitro-5-iodoquinoline-l-oxide 
4-Nitro-5-iodoquinoline-l-oxide was prepared in 437o yield from 
5-iodoquinoline-l-oxide (c.f. F (i)) by nitration under the conditions 
for the preparation of 4-nitro-quinoline-l-oxide above (c.f. G (i)) 
m.p. 234-237° dec. (Found: C, 33.8; H, 1.5; N, 8.4. C^H^IN^O^ 
requires: C, 34.2; H, 1.6; N, 8.9%). 5 8.60, 8.40 (2H, 2d, J 6.8 Hz; 
H2 and H3), 8.10 (IH, 2d, ^ ^ ^ 7.2 Hz, J^ ^ 8.2 Hz; H7). 
(ii) 4-Nitro-6-iodoquinoline-l-oxide 
4-Nitro-6-iodoquinoline-1-oxide was prepared in 5 3 7 o yield from 
6-iodoquinoline (c.f. C (iii)) which had been converted to the -1-oxide 
but only isolated as a crude product on evaporation of the solvent, by 
nitration under the conditions for the preparation of 4-nitroquinoline-
1-oxide (c.f. G (i)) above m.p. 157-161°. 
J. Amino-nitro-quinolines 
(i) 4-Amino-5-nitroquinoline 
4-Amino-5-nitroguinoline was prepared from 4-chloro-5-nitroquinoline 
(c.f. L (i)) by reaction in refluxing phenol solution with dry ammonia 
73 
under the conditions described by Keneford et al. giving a 5 3 7 o yield 
or at 1 4 0 - 1 5 0 ° when a 7 5 7 o yield was obtained. This compound was 
isolated as the monohydrate m.p. 7 3 - 7 4 . (Found: C, 5 2 . 2 ; H, 4.2; 
N, 2 0 . 5 , CgH^N^O^.H^O requires: G, 5 2 . 2 ; H, 4 . 4 ; N, 2 0 . 3 % ) . On drying 
anhydrous 4-amino-5-nitroquinoline was obtained of m . p . 1 2 1 - 1 2 2 ° . 
(Found: C, 57.3; H, 3.8; N, 22.0. C^H^N^O^ requires: C, 57.1; H, 3.7; 
N , 2 2 . 2 % ) . 5 8 . 5 0 , 6 . 9 4 ( 2 H , 2 d , J 5 . 4 H z ; H 2 a n d H 3 ) , 8 . 0 9 ( I H , 2 d , 
^ ^ 7.6 Hz, J^ g 2.1 Hz; H6), 7.64 (IH, t, J^^^ 7.6 Hz, J^^g 7.5 Hz; 
H7), 7.85 (IH, m; H8), 6.16 (2H, s; NH^). 
(ii) 4-Amino-6-nitroquinoline 
4-Amino-6-nitroquinoline was prepared in 83% yield from 4-chloro-
6-nitroquinoline (c.f. L (ii)) by reaction in refluxing phenol with 
7 dry ammonia as described by Keneford et al, m.p. 314-315° dec. 
"7 (lit. 310-313°). (Found: C, 56.8; H, 3.8; N, 21.9. Calc. for 
22.27o). (At 100 MHz) 68.35, 6.62 
(2H, 2d, J 5.3 Hz; H2 and H3), 9.24 (IH, d, J 2.2 Hz, H5), 8.24 J, / 
(IH, 2d, J^^^ 2.2 Hz, J^^g 9.1 Hz; H7), 7.81 (IH, m; H8), 7.37 (2H,s; 
NH^). 
(iii) 4-Amino-7-nitroquinoline 
4-Amino-7-Nitroquinoline was prepared in 11% yield from 4-chloro-
7-nitroquinoline (c.f. L (iii)) by reaction in refluxing phenol with 
73 o 
dry ammonia under the conditions used above m.p. 300-301° dec. 
(Found: C, 56.8; H, 3.7; N, 22.2. C^H^N^O^ requires: C, 57.1; H, 3.7; 
N, 22.27o). 6 8 . 5 2 , 6.78 (2H, 2d, J 5.2 Hz; H2 and H3), 8.45 (IH, d, 
J^ ^ 9.4 Hz; H5), 8.09 (IH, 2d, J^ ^ 9.4 Hz, J^ g 2.4 Hz; H6), 8.58 
(IH, d, ^ o 2.4 Hz; H8), 7.17 (2H, s; NH.). •~o , o L 
K. Diamino Quinolines 
(i) 4,5-Diaminoquinoline 
(a) The attempted preparation of 4,5-diaminoquinoline 
from 4-amino-5-nitroquinoline (c.f. J (i)) by reduction with stannous 
73 chloride gave only starting material. 
(b) The attempted preparation of 4,5-diaminoquinoline 
from 4-amino-5-nitroquinoline in acetic acid as solvent by catalytic 
reduction with hydrogen using a palladium on charcoal catalyst gave 
an acetate salt which sintered at>100° and finally melted at 172-173°. 
(ii) 4,6-Diaminoquinoline 
4,6-Diaminoquinoline was prepared in 607» yield from 4-amino-6-
nitroquinoline (c.f. J (ii)) by reduction with stannous chloride as 
described by Keneford at al.^^ m.p. 215-215.5° (lit.^^ 214°). (Found: 
C, 67.7; H, 5.7; N, 26.1. Gale, for G^H^N^: G, 67.9; H, 5.7; N, 26.4%). 
68.00, 6.38 (2H, 2d, J 5.0 Hz; H2 and H3), 6.92 (IH, 2d, J. ^ 2.0 Hz, J, / 
-5,8 ^5 7 :i7 8 H7), 7.50 
(IH, m; H8), 6.17 (2H, s; NH^), 5.08 (2H, s; NH^). 
(iii) 4,7-Diaminoquinoline 
(a) 4,7-Diaminoquinoline was prepared in 807» yield from 
4-amino-7-nitroquinoline (c.f. J (iii)) by reduction with stannous 
7 3 o 
chloride as for 4,6-diaminoquinoline m.p. 2 1 1 - 2 1 3 . (Found: G , 6 7 . 9 ; 
H, 5 . 9 ; N , 2 6 . 4 . C^H^N^ requires; G , 6 7 . 9 ; H, 5 . 7 : N , 2 6 . 4 7 o ) . 6 8 . 0 2 , 
6 . 2 0 (2H, 2d, J 5.2 Hz; H2 and H3, 7 . 7 9 (IH, d, J 9.5 Hz; H5), 6.85 J , D 
(IH, 2d, J^ ^ 9.5 Hz, g 2.3 Hz H6), 6.85 (IH, d, ¿^ ^ 2.3 Hz; H8), 
6.40 (2H, s; NH^), 5.03 (2H, s; NH^). 
(b) The preparation of 4,7-diaminoquinoline from 4,7-
dinitroquinoline-l-oxide (c.f. H (iii)) was attempted by catalytic 
reduction in glacial acetic acid containing a trace of hydrogen chloride 
with hydrogen at atmospheric pressure and palladium on charcoal catalyst. 
The rate of gas absorption was slow and after 5 hours reaction in-
sufficient product was isolated for identification. 
L. Halogeno-nitroquinolines 
(i) 4-Ghloro-5-nitroquinoline 
4-Ghloro-5-nitroquinoline was prepared from 4,5-dinitroquinoline-
1-oxide (c.f. H (i)) by reaction with phosphorus trichloride in 
chloroform as described by Hamana^^ for the preparation of 4-chloro-
quinoline from 4-nitroquinoline-1-oxide. The product was isolated 
from the reaction mixture after excess reagent was hydrolysed with 
water, the chloroform removed by distillation and the solution 
neutralised to give a 7 0 7 o yield of 4-chloro-5-nitroquinoline, m.p. 
o 32 
152-154 (lit. 150°). (Found: C, 52.1; H, 2.5; N, 13.0. Calc. 
for C^H^Cl N^O^: C, 51.8; H, 2.4; N, 13.4%). 5(in CD CI3) 8.84, 
7.60 (2H, 2d, J 4.7 Hz; H2 and H3), 7.72-7.82 (2H, m; H6 and H8), 
8.30 (IH, m; H7). 
(ii) 4-Chloro-6-nitroquinoline 
4-Ghloro-6-nitroquinoline was prepared in ITL yield from 4,6-
dinitroquinoline-l-oxide (c.f. H (ii)) by reaction with phosphorus 
trichloride in chloroform as used for the preparation of 4-chloro-5-o 3 ̂  o 
nitroquinoline above m.p, 144-145" (lit."-" 142.5''). (Found: C, 51.5; 
H, 2.5; N, 13.1. Calc. for C^H^Cl N^O^: C, 51.8; H, 2.4; N, 13.1%). 
6(in CDCl^) 8.92, 7.62 (2H, 2d, J 4.8 Hz; H2 and H3), 9.13 (IH, 2d, 
J^ ^ 2.5 Hz, J. o 0.7 Hz; H5), 8.49 (IH, 2d, J. ^ 2.5 Hz, J^ . 9.1 —J , / —J , o —J , / —/ , o Hz; H7), 8.20 (IH, m; H8). 
(iii) 4-Chloro-7-nitroquinoline 
(a) 4-Chloro-7-nitroquinoline was prepared in 8 5 7 o yield 
from 4,7-dinitroquinoline-l-oxide (c.f. H (iii)) by reaction with 
phosphorus trichloride in chloroform as used in the preparation of 
4-chloro-5-nitroquinoline above m.p. 171-173°. (Found: C, 51.7; 
H, 2.3; N, 13.3. C^H^CIN^O^ requires: C, 51.8; H, 2.4; N, 13.1%). 
6(in CD Cl^) 8.93, 7.65 (2H, 2d, J 4.7 Hz; H2 and H3), 8.34-8.39 
(2H, m; H5 and H6), 8.96 (IH, m; H8). 
(b) 4-Hydroxy-7-nitroquinoline was prepared in 547o yield 
from 3-carboxy-4-hydroxy-7-nitroquinoline (c.f. P (i)) by decarboxy-
7 2 
lation of the silver salt in Dowtherm A m.p. 317-320°. (Found: C, 
56.6; H, 3.1; N, 14.6. C^H^N^O^ requires: G, 56.8; H, 3.2; N, 14.8%). 
4-Chloro-7-nitroquinoline was prepared from this compound by reaction 
with phosphorus oxychloride as described for 4-chloro-6-nitroquinoline.^^ 
The product isolated of m.p. 173-174° showed no depression of melting 
point with and could not be separated by thin layer chromatography 
from authentic material. 
(iv) 4-Nitro-5-iodoquinoline 
4-Nitro-5-iodoquinoline was prepared from 4-nitro-5-iodoquinoline-
1-oxide (c.f. I (i)) by reaction with phosphorus trichloride in 
chloroform, as used to prepare 4-chloro-5-nitroquinoline above, of 
m.p. 157-159°. (Found: C, 35.9; H, 1.8; N, 8.9. C^H^IN^O^ requires: 
C, 36.0; H, 1.7; N, 9.3%). 58.93, 7.67 (2H, 2d, J 4.6 Hz; H2 and H3), 
7.80-7.89 (2H, m; H6 and H8), 8.37 (IH, t, J, ^ 5.0 Hz, J^ ^ 5.0 Hz; H7). —D , / —/ , O 
M. Halogeno-Amino quinolines 
(i) 4-Amino-6-iodoquinoline 
(a) 4-Amino-6-iodoquinoline was prepared in 8 5 7 o yield from 
4-chloro-6-iodoquinoline (c.f. N (i)) by reaction in refluxing phenol 
solution with dry ammonia as used for the preparation of 4-amino-6-
nitroquinoline above m.p. 222.5-223.5°. (Found: G, 40.3; H, 2.7; N, 
10.3. G^H^IN^ requires: G, 40.0, H, 2.6; N, 10.4%). 68.37, 6.61 
(2H, 2d, J 5.2 Hz, H2 and H3), 8.61 (IH, d, J^ g 1 . 8 Hz; H5), 7.57 
(IH, d, J^ g 8.9 Hz; H7), 7.88 (IH, m; H8), 6.87 (2H,s; NH^). 
(b) 4-Ainino-6-iodoquinoline was prepared from 4,6-
diaminoquincline (c.f. K (ii)) by the Sandmeyer reaction on the 
250 |iM scale with reagents at 0.05 M concentration. The diamino-
quinoline was diazotised with an equimolar quantity of potassium 
nitrite after which an equimolar quantity of potassium iodide, was 
added and the product isolated through chloroform to give 4-amino-6-
iodoquinoline of m.p. 211-214° identical (mixed m . p . , t.l.c. and 
infrared spectrum) with the above material. 
(ii) 4-Amino-7-iodoquinoline 
(a) 4-Amino-7-iodoquinoline was prepared in yield 
from 4-chloro-7-iodoquinoline (c.f. N (ii)) by reaction in refluxing 
phenol with dry ammonia as used for the preparation of 4-amino-6-
nitroquinoline above m.p. 197-198°. (Found: C, 39.8; H, 2.6; N, 10.1 
C.H^IN^ requires: C, 40.0; H, 2.6; N, 10.47»). 6 8.30, 6.58 (2H, 2d, 
9 / L 
J 5.2 Hz; H2 and H3), 7o97 (IH, d, J^ ^ 8.9 Hz; H5), 7o63 (IH, 2d, 
J^ ^ 8.9 Hz, J^ g 1.3 Hz; H6), 8.17 (IH, d, 1.2 Hz; H8), 6.84 
(2H, s; NH^). 
(b) 4-Amino-7-iodoquinoline was prepared from 4,7-
diaminoquinoline (c.f. K (iii)) by the Sandmeyer reaction on the 250 
jiM scale and as for the preparation of 4-amino-6-iodoquinoline above. 
The product had m.p. 188-193° and was identical (mixed m.p., t.l.c. 
and infrared spectrum) with the above material. 
(iii) 4-Chloro-5-Aminoquinoline 
The reduction of the nitro group in 4-chloro-5-nitroquinoline 
f« L (i)) with hydrogen at atmospheric pressure was attempted in 
ethanol solution using platinum oxide catalyst. No product correspond-
ing to an aminochloroquinoline could be isolated from the reaction. 
C O 
The attempted reduction with iron in the presence of chloride ions 
and iron and acetic acid^^'^^ also proved unsuccessful. 
(iv) 4-Chloro-7-aminoquinoline 
The attempted preparation of 4-chloro-7-aminoquinoline from 
4-chloro-7-nitroquinoline by reduction of the nitro group with sodium 
dithionate in 607o ethanol under reflux gave starting material. Only 
7-aminoquinoline was isolated from the attempted reduction with hydrogen 
at atmospheric pressure using a palladium on charcoal catalyst and 
acetic acid as solvent. 
N. Dihalogenoquinolines 
(i) 4-Chloro-6-iodoquinoline 
4-Chloro-6-iodoquinoline was prepared from 3-carboxy-4-hydroxy-6-
iodoquinoline (c.f. 0 (i)) by decarboxylation followed by reaction with 
phosphorus oxychloride under the conditions described by Riegel et al^^ 
for the preparation of 4-chloroquinoline giving a steam volatile 
product of m.p. 142-143°. (Found: C, 37.3; H, 1.8; N, 4<.8. C^H^Cl IN 
requires: C, 37.3; H, 1.7; N, 4.8%). 5 (in CD Cl^) 8.82, 7.63 (2H, 2d, 
J 4.7 Hz; H2 and H3), 8.58 (IH, d, J^ g 1.8 Hz; H5), 7.81 (IH, d, J^^g 
8.9 Hz; H7), 8.07 (IH, m; H8). 
(ii) 4-Chloro-7-iodoquinoline 
4-Chloro-7-iodoquinoline was prepared from 3-carboxy-4-hydroxy-7-
iodoquinoline (c.f. 0 (ii)) by decarboxylation then reaction with 
phosphorus oxychloride as for the preparation of 4-chloro-6-iodo-
quinoline, giving a product of m.p. 100-101° (lit.^^^ 101-102°). 
(Found: C, 37.7; H, 1.8; N, 4.8. Calc. for C^H^CIIN: C, 37.3, 
H, 1.7; N, 4.8%). 5 (in CD Cl^) 8.74, 6.58 (2H, 2d, J 4.7 Hz; H2 and 
H3), 7.87-7.89 (2H, m; H5 and H6), 8.54 (IH, m; H8). 
0. Carboxy-Hydroxy-Halogenoquinolines 
(i) 3-Carboxy-4-hydroxy-6-iodoquinoline 
3-Carboxy-4-hydroxy-6-iodoquinoline was prepared from ethyl 
carbethoxy-p -(4-iodophenylamino)-aerylate (c.f. Q (ii)) by cyclisation 
then hydrolysis of the ester (not isolated) under the conditions 
43 
described by Price and Roberts for the preparation of 3-carboxy-4-
hydroxy-7-chloroquinoline giving a product of m.p. 297-298° dec. 
(Found: C, 38.1; H, 1.9; N, 4.3. C^^H^INO^ requires: C, 38.1; H, 1.9; 
N, 4.5%). 
(ii) 3-Carboxy-4-hydroxy-7-iodoquinoline 
3-Carboxv-4-hvdroxy-7-iodoquinoline was prepared from ethyl 
carbethoxy-p-(3-iodophenylamino)-acrylate (c.f. Q (i)) by the reactions 
and conditions for the above compound giving first a 797o yield of o 25 
3-carbethoxy-4-hydroxy-7-iodoquinoline m.p. 253-256 subl. (lit. 
subl. 255°) which was hydrolysed in 98% yield to the acid m.p. 273-275° 
(lit.^^ 278°). 
P. Carboxy-hydroxy-nitroquinolines 
(i) 3-Carboxy-4-hydroxy-7-nitroquinoline 
3-Carboxy-4-hydroxy-7-nitroquinoline was prepared from ethyl 
carbethoxy-p-(3-nitrophenylamino)-acrylate (c.f. Q (iii)) as for the 
above compounds by cyclisation to 3-carbethoxy-4-hydroxy-7-nitro-
quinoline (not isolated) and hydrolysis of the ester to the acid m.p. 
287° dec. (Found: C, 51.2; H, 2.9; N, 11.8. C^^H^N^O^ requires: 
C, 51.3; H, 2.6; N, 11.9%). 
Q. Ethyl Carbethoxy- -(monosubstituted pheny1amino)-aery1ates 
(i) Ethyl Carbethoxy- p-(3-iodophenylamino)-acrylate was 
prepared from 3-iodoaniline by condensation with ethoxymethylene 
^ 3 
malonic ester giving 89% yield of product m.p. 87.5-89® (lit.^^ 
88-89°). 
(ii) Ethyl carbethoxy-p-(4-iodophenylamino)-acrvlate, prepared 
from 4-iodoaniline by condensation with ethoxymethy1enemaIonic ester , 
had m.p. 130-131°. (Found: C, 43.3; H, 4.0; N, 3.6. C^^H^INO^ requires: 
C, 43.2; H, 4ol; N, 3.6%). 
(iii) Ethyl carbethoxy-p-(3-nitrophenylamino)-acrvlate was 
prepared from 3-nitroaniline by condensation with diethyl ethoxymethy-
43 o lene malonate to give a product of m.p. 81-82 . (Found: C, 54.7; 
H, 5.3; N, 8.9. C, 54.5; H, 5.2; N, 9.1%). 
R. Alkylamino-nitroquinolines 
(i) 4-(3-dimethylaminopropylamino)-7-nitroquinoline was prepared 
from 4-chloro-7-nitroquinoline (c.f. L (iii)) by the reaction under 
reflux with an excess of 3-dimethylaminopropylamine as in the preparation 
25 of the 7-iodo-compound . On dilution with water the product was 
isolated as the monohydrate m.p. 88°. (Found: C, 57.4; H, 6.7; N, 19.2. 
CwH, ON,O^.H.O requires: C, 57.5; H, 6.9; N, 19.1%). On drying the 14 lo 4 2 Z 
anhydrous base was obtained of m.p. 111.5-112°. (Found: C, 61.3; 
H, 6.6; N, 20.2. ^^^H^gN^O^ requires: C, 61.2; H, 6.6; N, 20.4%). 
68.54 (IH, m; H2), 6.66 (IH, d, J^ 3 5.0 Hz; H3), 8.39 8.07 (2H, m; 
H5 and H6), 8.56 (IH, m; H8), 7.65 (IH, s; NH), 3.37 (2H, m or t after 
D^O exchange; H 1^), 1.85 (2H, m; H 2^), 2.41 (2H, m; H 3 ^ , 2.20 
(6H, s; NMe^). 
S. Alky1amino-aminoquinolines 
(i) 4-(3-dimethylaminopropylamino)-7-aminoquinoline was prepared 
from 4-(3-dimethylaminopropylamino)-7-nitroquinoline (c.f. above) by 
7 3 
reduction of the nitro group with stannous chloride as for the 
preparation of diaminoquinolines. The product was isolated by 
precipitation of tin sulphides from the double salt and crystallised 
as the hydrochloride m.p. 211-213°. (Found: C, 43.4; H, 6.3; N, 14.9. 
requires: C, 43.2; H, 6.2; N, 14.57o). 68.21, 6.18 
(2H, 2d, J 5.3 Hz; H2 and H3), 7.84, 6.85 (2H, m; H5 and H6i 6.94 
(IH, m; H8), 6.78 (IH, s; NH), 5.37 (2H, s; NH^), 3.26 (2H, m; H 1^), 
I.83 (2H, m; H 2^), 2.28 (2H, m; H 3^), 2.16 (6H, s; NMe^). 
T Alkylamino-halogenoquinolines 
(i) 4-(3-dimethylaminopropylamino)-6-iodoquinoline was prepared 
from 4-chloro-6-iodoquinoline (c.f. N (i)) by the reaction under reflux 
in an excess of dimethylaminopropylamine and the product isolated as 
described for the preparation of chloroquine^^^, m.p. 99-100°. (Found: 
C, 46.9; H, 4.9; N, 11.9 . C^^^H^glN^ requires; C, 47.3; H, 5.1; N, 11.8%). 
5(in CD CI3) 8.48, 6.26 (2H, 2d, J 5.4 Hz; H2 and H3), 8.08 (IH, m; H5), 
7.71-7.76 (2H, m; H7 and H8), 8.70 (IH, s; NH), 3.31 (2H, m or t after 
D^O exchange; H 1^), 1.87 (2H, m; H 2^), 2.44 (2H, m; H 3^), 2.37 
(6H, S; NMe^). 
(ii) 4-(3-Dimethylaminopropylamino)-7-iodoquinoline 
(a) 4-(3-Dimethylaminopropylamino)-7-iodoquinoline was 
prepared from 4-chloro-7-iodoquinoline (c.f. N (ii)) by reaction with 
dimethylaminopropylamine as carried out for the preparation of the 
6-iodo-compound giving a 85% yield m.p. 100-101° (lit.^^ 101-103°). 
(Found: C, 46.9; H, 5.5; N, 11.5. Calc. for C, 47.3; io J 
H , 5 a ; N , 1 1 . 8 7 o ) . 5 ( i n C D C l ^ ) 8 . 4 4 , 6 . 2 5 ( 2 H , 2 d , J 5 . 2 H z ; H 2 a n d 
H3), 7.46 (IH, d, J. . 8.9 Hz; H5), 7.23 (IH, 2d, J^ ^ 8.9 Hz, J, ^ ~ J , O —D , O —D , O 
2.1 Hz; H6), 7.90 (IH, d, ̂  g 2.1 Hz; H8), 7.71 (IH, s; NH), 3.21 
(2H, m or t after D^O exchange; H 1^) 1.77 (2H, m; H 2^), 2.36 
(2H, m; H 3^) 2.20 (6H, s; NMe^). 
(b) 4-(3-Dimethylaminopropylamino)-7-iodoquinoline was 
prepared from 4-(3-dimethylaminopropylamino)-7-aminoquinoline (c.f. 
S (i)) on the 250 |iM scale by the Sandmeyer reaction as for the 
preparation of 4-amino-6-iodoquinoline (1. (i) (b) above. The product 
of m.p. 95° was identical (mixed m.p., t.l.c., infrared spectrum) with 
the material above. 
U. Amino-hydrazinoquinolines 
(i) 4-Amino-6-hydrazinoquinoline 
4-Amino-6-hydrazinoquinoline was prepared from 4,6-diaminoquinoline 
(c.f. K (ii)) by diazotisation of the 6-amino-group with an equimolar 
quantity of nitrous acid then reduction of the diazonium compound with 
74 
stannous chloride as described by Hunsberger et al. After 
precipitation of tin sulphides from the double salt^^ 4-amino-6-
hydrazinoquinol ine was isolated as the dihydrochloride in.p. 311-312 
lO 2 (lit. 302°). (Found: C, 43.9; H, 4.9; N, 22.5. Calc. for C^H.^N,. 
9 10 4 
2HC1: C, 43.7; H, 4.9; N, 22.7%). 
LABELLING OF DERIVATIVES 
A. By 
131 
All labelling techniques involving I were carried out in a 
well ventilated cell constructed of 10 cm thick lead bricks. Wherever 
possible reaction vessels were used in lead shielded containers and 
semi-remote handling techniques were employed. The labelled compounds 
prepared were not usually isolated as pure compounds but were formu-
lated as solutions for administration to animals. 131 
(i) 5-Iodoquinoline- I was prepared from 5-aminoquinoline by 
the Sandmeyer reaction on the 5 |iM scale (c. f. C (ii)). 0.1 ml of 
0.05 M solution of 5-aminoquinoline in approximately 2 M hydrochloric 
acid was injected through the rubber septum into a sealed 10 ml vial in 
an ice bath. 0.1 ml. of 0.05 M potassium nitrite solution was added 
and about 5 minutes later 0.1 ml of 50 mg/ml urea in about 2 M 131 
hydrochloric acid. 25 mCi of I in a solution usually less than 
0.2 ml and containing 5 |iM of potassium iodide was added. After 
standing 20 minutes and heating in a water bath to decompose the 
diazonium compound, 0.2 ml of 407» w/v sodium hydroxide solution was 
added to the cooled mixture and the contents of the vial were transfer-
red to an all glass micro still. With 0.1 ml of isotonic acetic acid 
(0.145 M) in the receiver (which was vented to a trap of gas absorption 
charcoal) cautious distillation was carried out until a few drops of 
distillate containing suspended iodoquinoline were seen to drop into 
the receiver. The receiver contents in a 10 ml vial were diluted with 
isotonic acetate buffer (pH 6.5) to give the concentration of radio-
activity required and then the solution was sterilised by autoclaving 
at 132*̂  for 6 minutes. 
131 (ii) 6-Iodoquinoline- I was prepared from 6-aminoquinoline by 
131 the Sandmeyer reaction as described for 5-iodoquinoline- I. 
131 (iii) 7-Iodoquinoline- I was prepared from 7-aminoquinoline 
hydrochloride by the Sandmeyer reaction as described for 5-iodo-
. ,. 131 quinoline- I. 
131 (iv) 4-Amino-6-iodoquinoline- I was prepared from 4,6-diamino-
quinoline by the Sandmeyer reaction on the 5|iM scale as described for 
131 
5-iodoquinoline- I but the product was separated from the reaction 
mixture by extraction into approximately 3 times the volume of chloro-
form. The extract was washed twice with an equal volume of 0.9 mg/ml 
sodium chloride solution and the product extracted back into 0.15 M 
acetic acid solution. This solution was diluted to the radioactive 
concentration required with pH 6.5 isotonic acetate buffer, filtered 
through an 0.22 [imillipore filter and sterilised by autoclaving at 
132° for 6 minutes. 131 
(v) 4-Amino-7-iodoquinoline- I was prepared from 4,7-diamino-
quinoline by the Sandmeyer reaction as described for 4-amino-6-iodo-
quinoline. 131 (vi) 4-(3-Dimethylaminopropylamino)-7-iodoquinoline- I 
(a) 4-(3-Dimethylaminopropylamino)-7-iodoquinoline-^^^I 
was prepared from 4-(3-d 
imethylaminopropylamino)7-aminoquinoline by the 
Sandmeyer reaction as described for 4-amino-6-iodoquinoline. (b) 4-(3-Dimethylaniinopropylamino)-7-iodoquinoline-^^^I 
was prepared from 4-(3-dimethylaminopropylamino)-7-iodoquinoline by 
16 25 131 isotopic exchange. ' 8 mCi of I were incorporated into the 
quinoline when 100 mg of the quinoline were reacted for 2.5 hours with 
1 o -1 
25 mCi of a (1.7 mCi/|ig iodine) solution of I. Only 7 mCi were 
incorporated into the quinoline when 100 mg of the quinoline were 
reacted for the same period and the same conditions with 150 mCi of 
1 O 1 a 0.85 mCi/|ig of iodine solution of I. 
(c) The preparation of 4-(3-dimethylaminopropylamino)-7-
131 
iodoquinoline- I from 4-(3-dimethylaminopropylamino)-7-iodoquinoline 
by isotopic exchange was attempted by autoclaving a solution of 100 mg 
of the quinoline in 5 ml of 0.01 N sulphuric acid at 120° for 1 hour 
with solution as sodium iodide. Less than 5% of the was 
incorporated into the quinoline. 
B. By ^H 3 
(i) Quinoline-5- H was prepared from 5-hydrazinoquinoline by 
reaction with an excess of tritiated water at 350 mCi/ml and copper 
sulphate under the conditions described for the preparation of • T ^ ̂ u quinoline-j- H. 
3 3 (ii) Quinoline-l-oxide-5- H was prepared from quinoline-5- H 
35 o 
by oxidation with hydrogen peroxide in acetic acid at 55-60 for 
20 hours and the crude product obtained by evaporation to dryness. 
4-Nitroquinoline-l-oxide-5- H was prepared from the crude 
3 o c 
quinoline-l-oxide-5- H by nitration as described by Ochiai for the 
preparation of 4-nitroquinoline-l-oxide,and isolated as a crude 
product m.p. 149-150° (lit.^^ 153-154°). 
(iv) 4-Chloroquinoline-5- H was prepared from the crude 4-nitro 
3 
quinoline-l-oxide-5- H by reaction with phosphorus trichloride in 
chloroform as described by Hamana^^ for the preparation of 4-chloro-
quinoline. The crude product was isolated by the evaporation of 
chloroform from the extracts. 
(v) 4-Aminoquinoline-5- H was prepared from 4-chloroquinoline-
5-^H by reaction in refluxing phenol solution with dry ammonia^^ and 
isolated by extraction into chloroform. On gentle heating to 
evaporate the solvent the anhydrous base was obtained m.p, 145-148° 
53 o 
(lit. 154-155 ) identical (mixed m.p», t.l.c., infrared spectrum) 
with authentic material prepared above, and specific activity 2.7 
mCi/mM. 
(vi) 4-amino-6-hydrazinoquinoline was liberated from an aqueous 
solution containing 0.1 mM of the dihydrochloride and extracted into 
ether. The combined extracts in a 10 ml vial were evaporated rapidly 
to dryness then 30 mg of anhydrous copper sulphate with 0.5 ml of 
60 mCi/ml tritiated water were autoclaved for 1 hour at 135° with the 
contents of the vial. The mixture was extracted with chloroform from 
which negligible quantity of a radioactive product was recovered. 
C. Stability of the Labelled Material 131 (i) 4-(3-Dimethylaminopropylamino-7-iodoquinoline- I. 
(a) The proportion of I as free iodide was determined 
by thin layer chromatography in a 10 |iCi/ml solution of the hydro-
chloride of 4-(3-dimethylaminopropylamino)-7-iodoquinoline-^^^I at a 
specific activity of 28 mCi/mM then the solution was divided and one 
part autoclaved at 120° for 30 minutes. To the other part sodium 
chloride was added to give a 9 mg/ml solution and it was also autoclaved, 
131 
(b) The proportion of I as free iodide ions was 
determined for 4-(3-dimethylaminopropylamino)-7-iodoquinoline-^^^I 
in 0.005 M sulphuric acid, at the concentration used above, before 
and after autoclaving and after the addition of sodium chloride and 
autoclaving as above. 131 (c) The proportion of I as free iodide was then 
1 O 1 
determined for 4-(3-dimethylaminopropylamino)-7-iodoquinoline- I 
in 0.04 M citric acid solution at the concentration used above before 
and after autoclaving. 
(d) 20 ml of a solution of, 4-(3-dimethylaminopropylamino) 
131 -7-iodoquinoline- I in 0.04 M citric acid as used above was passed 
3 through an anion exchange column 4 cm long containing 2.5 cm of Bio 
131 Rad AGl X 8, 100-200 mesh, citrate form and the I as free iodide ions 
determined. 
131 (e) The radiochemical purity of 1 labelled 4-(3-
dimethylaminopropylamino)-7-iodoquinoline at a specific activity of 
5 mCi/|iM in an autoclaved solution of acetate buffer was measured by 
t.l.c. after preparation. 
(ii) Halogeno-4-aminoquinolines 
107 
131 
The radiochemical purity of I labelled 4-amino-6-iodo- and 
4-amino-7-iodoquinoline in an autoclaved solution of acetate buffer 
was determined by t.l.c. over a number of days after preparation. 
The results are shown in Table 3,, (p.46). 
(iii) Monohalogenoquinolines 131 
The radiochemical purity of I labelled 5-iodo,6-iodo and 
7-iodo-quinolines was determined in solutions as in (ii) above. The 
results are shown in Table 3. 
5. DISTRIBUTION OF LABELLED MATERIAL IN EXPERIMENTAL ANIMALS. 
A. lodoquinolines- I 
131 (i) 5-Iodoquinoline- I 
131 
0.2 ml of a 250 [iCi/ml sterile solution of 5-iodoquinoline- I 
at a specific activity of 5 mCi/|iM in acetate buffer solution was 
administered to four hooded rats by intraperitoneal (i.p.) injection. 
The rats were sacrificed consecutively at 24, 48, 72 and 96 hours after 
injection. Each animal was dissected, skinned and the skin divided 131 into pigmented and non-pigmented areas. The I distribution in the 
organs, carcass and excreta were determined. 
131 (ii) 6-Iodoquinoline- I 
131 
0.2 ml of a 250 |iCi/ml sterile solution of 6-iodoquinoline- I 
at a specific activity of 5 mCi/[j^ in a acetate buffer solution was 
administered to two hooded rats by i.p. injection. One rat was 
sacrificed at 72 hours and the other at 96 hours after injection. 131 Each animal was dissected, skinned and the I distribution in the 
organs, carcass and excreta determined. 
131 
(iii) 7-lodoquinoline- I 
131 The I distribution in organs, carcass and excreta was 
131 determined for 7-iodoquinoline- I administered to rats as described 
131 for 6-iodoquinoline- I above, 
131 B. 4-AminO"iodoquinolines- I 
131 
(i) 4-Amino-6-iodoquinoline- I 
(a) 0.2 ml of a 250 |iCi/ml sterile solution of 4-amino-6-
131 
iodoquinoline- I at a specific activity of 5 mCi/[JM in acetate buffer 
and diluted to 0.5 ml with isotonic saline was administered by i.p. 
injection to each of two hooded rats. One rat was sacrificed at 72 
and the other at 96 hours after injection. Each animal was dissected 
131 
and the I distribution determined in the organs and carcass. The 
131 
I concentrations in tissue were determined in the animal sacrificed 
96 hours after injection. 
(b) 0.2 ml and 0.8 ml of the solution of 4-amino-6-iodo-
131 
quinoline- I used above were administered orally to two hooded rats. 
The location of the radioactivity was assessed after 8, 24 and 96 
hours from the distribution of gamma photons recorded by a Nuclear 
Chicago Pho/Gamma HP Scintillation Camera using a pinhole collimator. 131 
96 hours after administration the animals were sacrificed and the I 
distributions and concentrations in tissue were determined. 
(ii) 4-Amino-7-iodoquinoline- I 
(a) 0.2 ml of a 250 [iCi/ml sterile solution of 4-amino-
131 7-iodoquinoline- I at a specific activity of 5 mCi/[iM diluted to 
0.5 ml with isotonic saline were administered by i.p. injection to 
two hooded rats. One animal was sacrificed at 72 and the other at 
131 96 hours after injection and the I distributions and concentrations 
131 in tissue determined as for 4-amino-6-iodoquinoline- I above. 
(b) 0.2 ml and 0.8 ml of the above solution of 4-amino-7-
131 iodoquinoline- I were administered orally to each of two rats and 
131 gamma camera pictures and I distributions and concentrations in 
131 tissues were determined as for 4-amino-6-iodoquinoline- I. 
6. DISTRIBUTION OF LABELLED MATERIAL IN TUMOUR BEARING ANIMALS. 
The animals used in these experiments were C-57 adult male mice 
into which 10^ cells of a highly pigmented B16 melanoma had been 
injected subcutaneously 10 days before the administration of the 
labelled materials. 
A. 4-Amino-iodoquinolines 
131 (i) 4-Amino-6-iodoquinoline- I 
(a) 0.1 ml of a 100 |iCi/ml sterile solution in acetate 
131 buffer of 4-amino-6-iodoquinoline- I at a specific activity of 
5 mCi/|iM was administered to three mice by i.p. injection. 96 hours 
131 
after injection the animals were sacrificed and the I distribution 
and concentrations in tissue were determined. 
(b) 0.1 of the above solution was administered to two 
mice orally and these were sacrificed 96 hours after administration 
1 31 and the I distributions and concentrations in tissue determined. 
131 (ii) 4-Aiiiino-7-iodoquinoline- I 
(a) 0.1 ml of a 100 [iCi/ml sterile solution in acetate 
buffer of 4-amino-7-iodoquinoline at a specific activity of 5 mCi/|iM 
was administered to three mice by i.p. injection. 96 hours after 
131 
injection the animals were sacrificed and the I distributions and 
concentrations in tissue were determined. 
(b) 0.1 ml of the above solution was administered orally 
131 
to two mice and the I distributions and concentrations in tissue 
determined in the animals which were sacrificed 96 hours after 
administration. 
B. 4-Alkyl-amino-iodoquinolines 131 (i) 4-(3-dimethylaminopropylamino)-7-iodoquinoline- I 
(a) 0.1 ml of a 100 |iCi/ml sterile solution in acetate 
131 
buffer of 4-(3-dimethylaminopropylamino)-7-iodoquinoline- I at a 
specific activity of 5 mCi/|iM was administered by i.p. injection to 
five mice. 96 hours after injection each animal was sacrificed, 131 
dissected and the I distributions and concentrations in tissue 
determined. 
(b) 0.3 ml of the above solution was administered only 
to one mouse which was sacrificed 96 hours after administration and 
the distribution was examined by the gamma camera. The animal 131 
was then dissected and the I distribution and concentrations in 
tissue determined. C. 4-Aminoquinoline 
3 
(i) 4-Aminoquinoline-5- H 
Ill 
(a) 0.1 ml and a 0.05 ml volume of a 18 |iCi/ml sterile 
3 
solution in acetate buffer of 4-aminoquinoline-5- H at a specific 
activity of 2.8 mCi/mM were administered by i.p. injection to two 
mice. The animals were sacrificed after 96 hours and the relative 3 concentrations of H in tissues determined. 
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